<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012234606
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Figoya
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FINGOLIMOD HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3010.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Dr. Reddy&#x2019;s Laboratories Ltd. Formulation Unit VII" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Dr. Reddy’s Laboratories Ltd. Formulation Unit VII
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2312]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA27
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Figoya is</strong><br />The active substance of Figoya Hard Capsules is fingolimod.<br /><strong>What Figoya is used for</strong><br />Figoya is used in adults and in children and adolescents (10 years of age and above) to treat relapsing-remitting multiple sclerosis (MS), more specifically in:<br />&bull; Patients who have failed to respond despite treatment with an MS treatment.<br />or<br />&bull; Patients who have rapidly evolving severe MS.<br />Figoya does not cure MS, but it helps to reduce the number of relapses and to slow down the progression of physical disabilities due to MS.<br /><strong>What is multiple sclerosis</strong><br />MS is a long-term condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the nerves from working properly. This is called demyelination.<br />Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms that reflect inflammation within the CNS. Symptoms vary from patient to patient but typically involve walking difficulties, numbness, vision problems or disturbed balance. Symptoms of a relapse may disappear completely when the relapse is over, but some problems may remain.</p><p><strong>How Figoya works</strong><br />Figoya helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This limits nerve damage caused by MS. Figoya also reduces some of the immune reactions of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Figoya</strong></p><p>&bull; If you are allergic to fingolimod or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you have a lowered immune response (due to an immunodeficiency syndrome, a disease or to medicines that suppress the immune system).<br />&bull; If you have a severe active infection or active chronic infection such as hepatitis or tuberculosis.<br />&bull; If you have an active cancer.<br />&bull; If you have severe liver problems.<br />&bull; If, in the last 6 months, you have had heart attack, angina, stroke or warning of a stroke or certain types of heart failure.<br />&bull; If you have certain types of irregular or abnormal heartbeat (arrhythmia), including patients in whom the electrocardiogram (ECG) shows prolonged QT interval before starting Figoya.<br />&bull; If you are taking or have recently taken medicine for irregular heartbeat such as quinidine, disopyramide, amiodarone or sotalol.<br />&bull; If you are pregnant or a woman of childbearing potential not using effective contraception.<br />If this applies to you or you are unsure, talk to your doctor before taking Figoya.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Figoya:<br />&bull; If you have severe breathing problems during sleep (severe sleep apnoea).<br />&bull; If you have been told you have an abnormal electrocardiogram.<br />&bull; If you suffer from symptoms of slow heart rate (e.g. dizziness, nausea, or palpitations).<br />&bull; If you are taking or have recently taken medicines that slow your heart rate (such as beta blockers, verapamil, diltiazem or ivabradine, digoxin, anticholinesteratic agents or pilocarpine).<br />&bull; If you have a history of sudden loss of consciousness or fainting (syncope).<br />&bull; If you plan to get vaccinated.<br />&bull; If you have never had chickenpox.<br />&bull; If you have or have had visual disturbances or other signs of swelling in the central vision area (macula) at the back of the eye (a condition known as macular oedema, see below), inflammation or infection of the eye (uveitis), or if you have diabetes (which can cause eye problems).<br />&bull; If you have liver problems.<br />&bull; If you have high blood pressure that cannot be controlled by medicines.<br />&bull; If you have severe lung problems or smoker&rsquo;s cough.<br />If any of these applies to you, or you are unsure, talk to your doctor before taking Figoya.<br />Slow heart rate (bradycardia) and irregular heartbeat<br />At the beginning of treatment or after taking the first dose of 0.5 mg when you switch from a 0.25 mg daily dose, fingolimod causes the heart rate to slow down.<br />As a result, you may feel dizzy or tired, or be consciously aware of your heartbeat, or your blood pressure may drop. If these effects are severe, tell your doctor, because you may need treatment right away. Fingolimod can also cause an irregular heartbeat, especially after the first dose. Irregular heartbeat usually returns to normal in less than one day. Slow heart rate usually returns to normal within one month. During this period, no clinically significant heart rate effects are usually expected.<br />Your doctor will ask you to stay at the surgery or clinic for at least 6 hours, with hourly pulse and blood pressure measurements, after taking the first dose of fingolimod or after taking the first dose of 0.5 mg when you switch from a 0.25 mg daily dose, so that appropriate measures can be taken in the event of side effects that occur at the start of treatment. You should have an electrocardiogram performed prior to the first dose of fingolimod and after the 6-hour monitoring period. Your doctor may monitor your electrocardiogram continuously during that time. If after the 6-hour period you have a very slow or decreasing heart rate, or if your electrocardiogram shows abnormalities, you may need to be monitored for a longer period (at least 2 more hours and possibly overnight) until these have resolved. The same may apply if you&nbsp;break was and how long you had been taking fingolimod before the break.<br />If you have, or if you are at risk for, an irregular or abnormal heartbeat, if your electrocardiogram is abnormal, or if you have heart disease or heart failure, fingolimod may not be appropriate for you.</p><p>If you have a history of sudden loss of consciousness or decreased heart rate, fingolimod may not be appropriate for you. You will be evaluated by a cardiologist (heart specialist) to advise how you should start treatment with fingolimod, including overnight monitoring.</p><p>If you are taking medicines that can cause your heart rate to decrease, fingolimod may not be appropriate for you. You will need to be evaluated by a cardiologist, who will check whether you can be switched to alternative medicine that does not decrease your heart rate in order to allow treatment with fingolimod. If such a switch is impossible, the cardiologist will advise how you should start treatment with fingolimod, including overnight monitoring.</p><p>If you have never had chickenpox<br />If you have never had chickenpox, your doctor will check your immunity against the virus that causes it (varicella zoster virus). If you are not protected against the virus, you may need a vaccination before you start treatment with Figoya. If this is the case, your doctor will delay the start of treatment with Figoya until one month after the full course of vaccination is completed.</p><p>Infections<br />Fingolimod lowers the white blood cell count (particularly the lymphocyte count). White blood cells fight infection. While you are taking Figoya (and for up to 2 months after you stop taking it), you may get infections more easily. Any infection that you already have may get worse. Infections could be serious and life-threatening. If you think you have an infection, have fever, feel like you have the flu, have shingles or have a headache accompanied by stiff neck, sensitivity to light, nausea, rash, and/or confusion or seizures (fits) (these may be symptoms of meningitis and/or encephalitis caused by a fungal or herpes viral infection), contact your doctor straight away, because it could be serious and life-threatening.</p><p>If you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms, talk to your doctor straight away, because these may be the symptoms of a rare brain disorder caused by infection and called progressive multifocal leukoencephalopathy (PML). PML is a serious condition that may lead to severe disability or death.</p><p>Your doctor will consider performing an MRI scan to evaluate this condition and will decide whether you need to stop taking Figoya.<br />Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported in patients treated with fingolimod. Your doctor will consider whether you need to have a vaccination against HPV before starting treatment. If you are a woman, your doctor will also recommend HPV screening.</p><p>Macular oedema<br />Before you start Figoya, if you have or have had visual disturbances or other signs of swelling in the central vision area (macula) at the back of the eye, inflammation or infection of the eye (uveitis) or diabetes, your doctor may want you to undergo an eye examination.</p><p>Your doctor may want you to undergo an eye examination 3 to 4 months after starting Figoya treatment.</p><p>The macula is a small area of the retina at the back of the eye, which enables you to see shapes, colours, and details clearly and sharply. Figoya may cause swelling in the macula, a condition that is known as macular oedema. The swelling usually happens in the first 4 months of Figoya treatment.<br />Your chance of developing macular oedema is higher if you have diabetes or have had an inflammation of the eye called uveitis. In these cases your doctor will want you to undergo regular eye examinations in order to detect macular oedema.</p><p>If you have had macular oedema, talk to your doctor before you resume treatment with Figoya.</p><p>Macular oedema can cause some of the same vision symptoms as an MS attack (optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. Your doctor may want you to undergo an eye examination, especially if:<br />&bull; The centre of your vision gets blurry or has shadows.<br />&bull; You develop a blind spot in the centre of your vision.<br />&bull; You have problems seeing colours or fine detail</p><p>Liver function tests<br />If you have severe liver problems, you should not take Figoya. Figoya may affect your liver function. You will probably not notice any symptoms but if you notice yellowing of your skin or the whites of your eyes, abnormally dark urine (brown coloured), pain on the right side of your stomach area (abdomen), tiredness, feeling less hungry then usual or unexplained nausea and vomiting, tell your doctor straight away.<br />If you get any of these symptoms after starting Figoya, tell your doctor straight away.<br />Before, during and after the treatment, your doctor will request blood tests to monitor your liver function. If your test results indicate a problem with your liver you may have to interrupt treatment with Figoya.</p><p>High blood pressure<br />As Figoya causes a slight elevation of blood pressure, your doctor may want to check your blood pressure regularly.<br />Lung problems<br />Figoya has a slight effect on the lung function. Patients with severe lung problems or with smoker&rsquo;s cough may have a higher chance of developing side effects.</p><p>Blood count<br />The desired effect of Figoya treatment is to reduce the amount of white blood cells in your blood. This will usually go back to normal within 2 months of stopping treatment. If you need to have any blood tests, tell the doctor that you are taking Figoya. Otherwise, it may not be possible for the doctor to understand the results of the test, and for certain types of blood test your doctor may need to take more blood than usual.<br />Before you start Figoya, your doctor will confirm whether you have enough white blood cells in your blood and may want to repeat a check regularly. In case you do not have enough white blood cells, you may have to interrupt treatment with Figoya.<br />Posterior reversible encephalopathy syndrome (PRES)<br />A condition called posterior reversible encephalopathy syndrome (PRES) has been rarely reported in MS patients treated with fingolimod.<br />Symptoms may include sudden onset of severe headache, confusion, seizures and vision changes. Tell your doctor straight away if you experience any of these symptoms during your treatment with Figoya, because it could be serious.<br />Cancer<br />Skin cancers have been reported in MS patients treated with fingolimod. Talk to your doctor straight away if you notice any skin nodules (e.g. shiny pearly nodules), patches or open sores that do not heal within weeks. Symptoms of skin cancer may include abnormal growth or changes of skin tissue (e.g. unusual moles) with a change in colour, shape or size over time. Before you start Figoya, a skin examination is required to check whether you have any skin nodules. Your doctor will also carry out regular skin examinations during your treatment with Figoya. If you develop problems with your skin, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis.<br />A type of cancer of the lymphatic system (lymphoma) has been reported in MS patients treated with fingolimod.</p><p>Exposure to the sun and protection against the sun<br />Figoya weakens your immune system. This increases your risk of developing cancers, in particular skin cancers. You should limit your exposure to the sun and UV rays by:<br />&bull;&nbsp;Wearing appropriate protective clothing.<br />&bull;&nbsp;Regularly applying sunscreen with a high degree of UV protection.<br />Unusual brain lesions associated with MS relapse<br />Rare cases of unusually large brain lesions associated with MS relapse have been reported in patients treated with fingolimod. In case of severe relapse, your doctor will consider performing MRI to evaluate this condition and will decide whether you&nbsp;need to stop taking Figoya.</p><p>Switch from other treatments to Figoya<br />Your doctor may switch you directly from beta interferon, glatiramer acetate or dimethyl fumarate to fingolimod if there are no signs of abnormalities caused by your previous treatment. Your doctor may have to do a blood test in order to exclude such abnormalities. After stopping natalizumab you may have to wait for 2-3 months before starting treatment with Figoya. To switch from teriflunomide, your doctor may advise you to wait for a certain time or to go through an accelerated elimination procedure. If you have been treated with alemtuzumab, a thorough evaluation and discussion with your doctor is required to decide if Figoya is appropriate for you.<br />Women of childbearing potential<br />If used during pregnancy, Figoya can harm the unborn baby. Before you start treatment with Figoya your doctor will explain the risk to you and ask you to do a pregnancy test in order to ensure that you are not pregnant. Your doctor will give you a card which explains why you should not become pregnant while taking Figoya. It also explains what you should do to avoid becoming pregnant while you are taking Figoya. You must use effective contraception during treatment and for 2 months after stopping treatment (see section &ldquo;Pregnancy and breastfeeding&rdquo;).<br />Worsening of MS after stopping Figoya treatment<br />Do not stop taking Figoya or change your dose without talking to your doctor first.<br />Tell your doctor straight away if you think your MS is getting worse after you have stopped treatment with Figoya. This could be serious (see &ldquo;If you stop taking Figoya&rdquo; in section 3, and also section 4, &ldquo;Possible side effects&rdquo;).</p><p><strong>Elderly</strong><br />Experience with fingolimod in elderly patients (over 65 years) is limited. Talk to your doctor if you have any concerns.<br /><strong>Children and adolescents</strong><br />Fingolimod is not intended for use in children below 10 years old as it has not been studied in MS patients in this age group.<br />The warnings and precautions listed above also apply to children and adolescents. The following information is particularly important for children and adolescents and their caregivers:<br />&bull; Before you start Figoya, your doctor will check your vaccination status. If you have not had certain vaccinations, it may be necessary for you to be given them before Figoya can be started.<br />&bull; The first time you take fingolimod, or when you switch from a 0.25 mg daily dose to a 0.5 mg daily dose, your doctor will monitor your heart rate and heartbeat (see &ldquo;Slow heart rate (bradycardia) and irregular heartbeat&rdquo; above).<br />&bull; If you experience convulsions or fits before or whilst taking Figoya, let your doctor know.<br />&bull; If you suffer from depression or anxiety or if you become depressed or anxious while you are taking Figoya, let your doctor know. You may need to be monitored more closely.&nbsp;</p><p><strong>Other medicines and Figoya</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you are taking any of the following medicines:<br />&bull;&nbsp;Medicines that suppress or modulate the immune system, including other medicines used to treat MS, such as beta interferon, glatiramer acetate, natalizumab, mitoxantrone, teriflunomide, dimethyl fumarate or alemtuzumab. You must not use Figoya together with such medicines as this could intensify the effect on the immune system (see also &ldquo;Do not take Figoya&rdquo;).<br />&bull;&nbsp;Corticosteroids, due to a possible added effect on the immune system.<br />&bull;&nbsp;Vaccines. If you need to receive a vaccine, seek your doctor&rsquo;s advice first. During and for up to 2 months after treatment with Figoya, you should not receive certain types of vaccine (live attenuated vaccines) as they could trigger the infection that they were supposed to prevent. Other vaccines may not work as well as usual if given during this period.<br />&bull;&nbsp;Medicines that slow the heartbeat (for example beta blockers, such as atenolol). Use of Figoya together with such medicines could intensify the effect on heartbeat in the first days after starting Figoya.<br />&bull;&nbsp;Medicines for irregular heartbeat, such as quinidine, disopyramide, amiodarone or sotalol. You must not use Figoya if you are taking such a medicine because it could intensify the effect on irregular heartbeat (see also &ldquo;Do not take Figoya&rdquo;).<br />&bull;&nbsp;Other medicines:<br />-&nbsp;Protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin.<br />-&nbsp;Carbamazepine, rifampicine, phenobarbital, phenytoin, efavirenz or St. John&rsquo;s Wort (potential risk of reduced efficacy of Figoya).</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<br />Pregnancy<br />Do not use Figoya during pregnancy, if you are trying to become pregnant or if you are a woman who could become pregnant and you are not using effective contraception. If Figoya is used during pregnancy, there is a risk of harm to the unborn baby.<br />The rate of congenital malformations observed in babies exposed to fingolimod during pregnancy is about 2 times the rate observed in the general population (in whom the rate of congenital malformations is about 2-3%). The most frequently reported malformations included cardiac, renal and musculoskeletal malformations.<br />Therefore, if you are a woman of childbearing potential:<br />&bull;&nbsp;Before you start treatment with Figoya your doctor will inform you about the risk to an unborn baby and ask you to do a pregnancy test in order to ensure that you are not pregnant, and,<br />&bull;&nbsp;You must use effective contraception while taking Figoya and for two months after you stop taking it to avoid becoming pregnant. Talk to your doctor about reliable methods of contraception.<br />Your doctor will give you a card which explains why you should not become pregnant while taking Figoya.<br />If you do become pregnant while taking Figoya, tell your doctor straight away. Your doctor will decide to stop treatment (see &ldquo;If you stop taking Figoya&rdquo; in section 3, and also section 4, &ldquo;Possible side effects&rdquo;). Specialised pre-natal monitoring will be performed.<br />Breastfeeding<br />You should not breastfeed while you are taking Figoya.<br />Figoya can pass into breast milk and there is a risk of serious side effects for the baby.</p><p><strong>Driving and using machines</strong><br />Your doctor will tell you whether your illness allows you to drive vehicles, including a bicycle, and use machines safely. Figoya is not expected to have an influence on your ability to drive and use machines.<br />However, at initiation of treatment you will have to stay at the doctor&rsquo;s surgery or clinic for 6 hours after taking the first dose of Figoya. Your ability to drive and use machines may be impaired during and potentially after this time period.<br /><strong>Figoya contains sodium lauryl sulphate</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Figoya will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.<br />Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />The recommended dose is:<br />Adults:<br />The dose is one 0.5 mg capsule per day.<br />Children and adolescents (10 years of age and above):<br />The dose depends on body weight:<br />&bull;&nbsp;Children and adolescents with body weight equal to or below 40 kg: one 0.25 mg&nbsp;capsule per day.</p><p>Fingolimod 0.5 mg hard capsules are not suitable for paediatric patients with body weight&le;40 kg. Other fingolimod-containing medicinal products are available in a lower strength (as 0.25 mg capsules).</p><p>&bull;&nbsp;Children and adolescents with body weight above 40 kg: one 0.5 mg capsule per day.<br />Children and adolescents who start on one 0.25 mg capsule per day and later reach a stable body weight above 40 kg will be instructed by their doctor to switch to one 0.5 mg capsule per day. In this case, it is recommended to repeat the first-dose observation period.<br />Do not exceed the recommended dose.<br />Figoya is for oral use.<br />Take Figoya once a day with a glass of water.<br />Figoya Hard Capsules should always be swallowed intact, without opening them. Figoya can be taken with or without food.<br />Taking Figoya at the same time each day will help you remember when to take your medicine. If you have questions about how long to take Figoya, talk to your doctor or your pharmacist.<br /><strong>If you take more Figoya than you should</strong><br />If you have taken too much Figoya, call your doctor straight away.</p><p><strong>If you forget to take Figoya</strong><br />If you have been taking Figoya for less than 1 month and you forget to take 1 dose for a whole day, call your doctor before you take the next dose. Your doctor may decide to keep you under observation at the time you take the next dose.<br />If you have been taking Figoya for at least 1 month and have forgotten to take your treatment for more than 2 weeks, call your doctor before you take the next dose.<br />Your doctor may decide to keep you under observation at the time you take the next dose. However, if you have forgotten to take your treatment for up to 2 weeks, you can take the next dose as planned.<br />Never take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Figoya</strong><br />Do not stop taking Figoya or change your dose without talking to your doctor first.<br />Figoya will stay in your body for up to 2 months after you stop taking it. Your white blood cell count (lymphocyte count) may also remain low during this time and the side effects described in this leaflet may still occur. After stopping Figoya you may have to wait for 6-8 weeks before starting a new MS treatment.<br />If you have to restart Figoya more than 2 weeks after you stop taking it, the effect on heart rate normally seen when treatment is first started may re-occur and you will need to be monitored at the doctor&rsquo;s surgery or clinic for re-initiation of treatment.<br />Do not restart Figoya after stopping it for more than two weeks without seeking advice from your doctor.</p><p>Your doctor will decide whether and how you need to be monitored after stopping Figoya. Tell your doctor straight away if you think your MS is getting worse after you have stopped treatment with Figoya. This could be serious.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Some side effects could be or could become serious.<br /><strong>Common (may affect up to 1 in 10 people):</strong><br />&bull;&nbsp;Coughing with phlegm, chest discomfort, fever (signs of lung disorders).<br />&bull;&nbsp;Herpes virus infection (shingles or herpes zoster) with symptoms such as blisters, burning, itching or pain of the skin, typically on the upper body or the face. Other symptoms may be fever and weakness in the early stages of infection, followed by numbness, itching or red patches with severe pain.<br />&bull;&nbsp;Slow heartbeat (bradycardia), irregular heart rhythm.<br />&bull;&nbsp;A type of skin cancer called basal cell carcinoma (BCC) which often appears as a pearly nodule, although it can also take other forms.<br />&bull;&nbsp;Depression and anxiety are known to occur with increased frequency in the MS population and have also been reported in paediatric patients treated with fingolimod.<br />&bull;&nbsp;Weight los</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong><br />&bull;&nbsp;Pneumonia with symptoms such as fever, cough, difficulty breathing.<br />&bull;&nbsp;Macular oedema (swelling in the central vision area of the retina at the back of the eye) with symptoms such as shadows or blind spot in the centre of the vision, blurred vision, problems seeing colours or details.<br />&bull;&nbsp;Reduction in blood platelets which increases risk of bleeding or bruising.<br />&bull;&nbsp;Malignant melanoma (a type of skin cancer which usually develops from an unusual mole).<br />Possible signs of melanoma include moles which may change size, shape, elevation or colour over time, or new moles. The moles may itch, bleed or ulcerate.<br />&bull;&nbsp;Convulsion, fits (more frequent in children and adolescents than in adults).</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong><br />&bull;&nbsp;A condition called posterior reversible encephalopathy syndrome (PRES). Symptoms may include sudden onset of severe headache, confusion, seizures and/or vision disturbances.<br />&bull;&nbsp;Lymphoma (a type of cancer that affects the lymph system).<br />&bull;&nbsp;Squamous cell carcinoma: a type of skin cancer which may present as a firm red nodule, a sore with crust, or a new sore on an existing scar.</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong><br />&bull;&nbsp;Electrocardiogram anomaly (T-wave inversion).<br />&bull;&nbsp;Tumour related to infection with human herpes virus 8 (Kaposi&rsquo;s sarcoma).<br />Not known (frequency cannot be estimated from the available data):<br />&bull;&nbsp;Allergic reactions, including symptoms of rash or itchy hives, swelling of lips, tongue or face, which are more likely to occur on the day you start fingolimod treatment.<br />&bull;&nbsp;Signs of liver disease (including liver failure), such as yellowing of your skin or the whites of your eyes (jaundice), nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (brown coloured), feeling less hungry than usual, tiredness and abnormal liver function tests. In a very small number of cases, liver failure could lead to liver transplantation.<br />&bull;&nbsp;Risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). The symptoms of PML may be similar to an MS relapse. Symptoms might also arise that you might not become aware of by yourself, such as changes in mood or behaviour, memory lapses, speech and communication difficulties, which your doctor may need to investigate further to rule out PML. Therefore, if you believe your MS is getting worse or if you or those close to you notice any new or unusual symptoms, it is very important that you speak to your doctor as soon as possible.<br />&bull;&nbsp;Cryptococcal infections (a type of fungal infection), including cryptococcal meningitis with symptoms such as headache accompanied by stiff neck, sensitivity to light, nausea, and/or confusion.<br />&bull;&nbsp;Merkel cell carcinoma (a type of skin cancer).<br />Possible signs of Merkel cell carcinoma include flesh-coloured or bluish-red, painless nodule, often on the face, head or neck. Merkel cell carcinoma can also present as a firm painless nodule or mass. Long-term exposure to the sun and a weak immune system can affect the risk of developing Merkel cell carcinoma.<br />&bull;&nbsp;After fingolimod treatment is stopped, symptoms of MS can return and may become worse than they were before or during treatment.<br />&bull;&nbsp;Autoimmune form of anaemia (decreased amount of red blood cells) where red blood cells are destroyed (autoimmune haemolytic anaemia).<br />If you experience any of these, tell your doctor straight away.</p><p><strong>Other side effects<br />Very common (may affect more than 1 in 10 people):</strong><br />&bull;&nbsp;Infection from flu virus with symptoms such as tiredness, chills, sore throat, aching in the joints or muscles, fever.<br />&bull;&nbsp;Feeling of pressure or pain in the cheeks and forehead (sinusitis).<br />&bull;&nbsp;Headache.<br />&bull;&nbsp;Diarrhoea.<br />&bull;&nbsp;Back pain.<br />&bull;&nbsp;Blood testing showing higher levels of liver enzymes.<br />&bull;&nbsp;Cough.<br /><strong>Common (may affect up to 1 in 10 people):</strong><br />&bull; Ringworm, a fungal infection of the skin (tinea versicolor).<br />&bull;&nbsp;Dizziness.<br />&bull;&nbsp;Severe headache often accompanied by nausea, vomiting and sensitivity to light (migraine).<br />&bull;&nbsp;Low level of white blood cells (lymphocytes, leucocytes).<br />&bull;&nbsp;Weakness.<br />&bull;&nbsp;Itchy, red, burning rash (eczema).<br />&bull;&nbsp;Itching.<br />&bull;&nbsp;Blood fat (triglycerides) level increased.<br />&bull;&nbsp;Hair loss.<br />&bull;&nbsp;Breathlessness.<br />&bull;&nbsp;Depression.<br />&bull;&nbsp;Blurred vision (see also the section on macular oedema under &ldquo;some side effects could be or could become serious&rdquo;).<br />&bull;&nbsp;Hypertension (fingolimod may cause a mild increase in blood pressure).<br />&bull;&nbsp;Muscle pain.<br />&bull;&nbsp;Joint pain.<br /><strong>Uncommon (may affect up to 1 in 100 people):</strong><br />&bull; Low level of certain white blood cells (neutrophils).<br />&bull;&nbsp;Depressed mood.<br />&bull;&nbsp;Nausea.<br /><strong>Rare (may affect up to 1 in 1,000 people):</strong><br />&bull;&nbsp;Cancer of the lymphatic system (lymphoma).<br />Not known (frequency cannot be estimated from the available data):<br />&bull;&nbsp;Peripheral swelling.<br />If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store below 30&deg;C.<br />Store in the original package in order to protect from moisture.<br />Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not use any pack that is damaged or shows signs of tampering.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is fingolimod.<br />Each hard capsule contains 0.5 mg f﻿i ngolimod (as hydrochloride).<br />The other ingredients are: Capsule content: betacyclodextrin and magnesium stearate. Capsule shell: iron oxide yellow, titanium dioxide, gelatin and sodium lauryl sulphate. Printing ink: shellac, black iron oxide and potassium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Figoya 0.5 mg Hard Capsules are white to off-white powder filled in size ‘3’ hard gelatin capsules with dark yellow opaque colored cap imprinted ‘FGM’ with black ink and white opaque colored body imprinted ‘0.5mg’ with black ink.
Pack size: 28 Hard Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Alrazi Pharmaceutical Industries Factory Co.,<br />2nd Industrial City, Street no. 67, Cross 110, P.O. Box 3992,<br />Dammam, Kingdom of Saudi Arabia<br />Tel.: +966 13 8281919,<br />Fax: +966 13 8281313,<br />E-mail: info@alrazi-pharma.com<br />Website: www.alrazi-pharma.com<br /><strong>Manufacturer</strong><br />Dr. Reddy&rsquo;s Laboratories Limited,<br />Formulation Technical Operations,<br />Unit-VII, P1 to P9 &amp; Q1 to Q5, Phase III,<br />VSEZ, Duvvada Visakhapatnam,<br />Andhra Pradesh, 530 046,<br />India (IND).</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو فيجويا</strong><br />المادة الفعّالة في فيجويا كبسولات صلبة هي فينجوليمود.<br />فيما يستخدم فيجويا<br />يستخدم فيجويا في البالغين والأطفال والمراهقين(0 سنوات من العمر فما فوق)لعلاج انتكاس التصلب<br />العصبي المتعدد وبشكل أكثر تحديداً في:<br />&middot;&nbsp;المرضى الذين فشلوا في الاستجابة على الرغم من خضوعهم لعلاج مرض التصلب العصبي المتعدد.<br />أو<br />&middot;&nbsp;المرضى الذين تطورت لديهم بسرعة شدة أعراض مرض التصلب العصبي المتعدد.<br />لا يعالج فيجويا مرض التصلب العصبي المتعدد، لكنه يساعد في تقليل عدد الانتكاسات والحد من تطور الإعاقة<br />الجسدية بسبب مرض التصلب العصبي المتعدد.</p><p><strong>ما هو مرض التصلب العصبي المتعدد</strong><br />مرض التصلب العصبي المتعدد هو حالة طويلة الأجل تؤثر على الجهاز العصبي المركزي، والذي يتكوّن من الدماغ والنخاع الشوكي. في مرض التصلب العصبي المتعدد يدمر الإلتهاب الغشاء الواقي (المسمى المايلين)&nbsp;حول الأعصاب في الجهاز العصبي المركزي ويوقف الأعصاب عن العمل بشكل صحيح. هذا مايسمى بإزالة المايلين.<br />يتميز مرض التصلب العصبي المتعدد بعدد من الهجمات المتكررة (الانتكاسات) لأعراض الجهاز العصبي التي تعكس وجود إلتهاب داخل الجهاز العصبي المركزي. تختلف الأعراض من مريض لآخر ولكنها عادة ما<br />تتضمن صعوبات في المشي، أو تنميل، أو مشاكل في الرؤية، أو اضطراب في التوازن. قد تختفي أعراض الانتكاس تماماً عند انتهاء الانتكاس، ولكن قد تبقى بعض المشاكل قائمة.<br /><strong>كيفية عمل فيجويا</strong><br />يساعد فيجويا على حماية الجهاز العصبي المركزي من الهجمات التي يتعرض لها عبر الجهاز المناعي عن طريق تقليل قدرة بعض خلايا الدم البيضاء (الخلايا الليمفاوية)&nbsp;من التحرك بحرية داخل الجسم ومنعها من<br />الوصول إلى الدماغ والنخاع الشوكي. هذا يؤدي إلى الحد من تلف الأعصاب الناجم عن مرض التصلب العصبي المتعدد. يقلل فيجويا أيضاً من بعض ردود الفعل المناعية لجسمك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول فيجويا﻿</strong><br />&middot;&nbsp;إذا كان لديك حساسية من فينجوليمود أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).<br />&middot;&nbsp;إذا كان لديك استجابة مناعية منخفضة (بسبب متلازمة نقص المناعة، أو بسبب مرض أو بسبب الأدوية<br />التي تثبط الجهاز المناعي).<br />&middot;&nbsp;إذا كان لديك عدوى نشطة شديدة أو عدوى مزمنة نشطة مثل إلتهاب الكبد أو السلّ.<br />&middot;&nbsp;إذا كنت تعاني من سرطان نشط.<br />&middot;&nbsp;إذا كنت تعاني من مشاكل شديدة في الكبد.<br />&middot;&nbsp;إذا كنت قد تعرضت خلال الستة أشهر الماضية لنوبة قلبية، أو ذبحة صدرية، أو سكتة دماغية أو تحذير من حدوث سكتة دماغية أو أنواع معينة من فشل القلب.<br />&middot;&nbsp;إذا كان لديك أنواع معينة من عدم انتظام ضربات القلب أو وجود اضطراب في ضربات القلب (اضطراب عند إجراء تخطيط القلب الكهربائي قبل QT النظم)، بما في ذلك المرضى الذين يظهر لديهم إطالة في فترة البدء في تناول فيجويا.<br />&middot;&nbsp;إذا كنت تتناول أو تناولت مؤخراً أدوية لعلاج عدم انتظام ضربات القلب مثل كينيدين، أو ديسوبيراميد، أو أميودارون أو سوتالول.<br />&middot;&nbsp;إذا كنتِ حاملاً أو امرأة في سن الإنجاب ولا تستخدمي وسائل منع الحمل الفعّالة.<br />إذا كان هذا ينطبق عليك أو كنت غير متأكد، تحدث إلى طبيبك قبل تناول فيجويا.</p><p><strong>الاحتياطات والتحذيرات</strong><br />تحدث إلى طبيبك قبل تناول فيجويا:<br />&middot;&nbsp;إذا كنت تعاني من مشاكل شديدة في التنفس أثناء النوم (ضيق شديد في التنفس أثناء النوم).<br />&middot;&nbsp;إذا تم إخبارك بأن لديك خلل في تخطيط القلب الكهربائي الخاص بك.<br />&middot;&nbsp;إذا كنت تعاني من أعراض بطء معدل ضربات القلب (مثل: الدوخة، أو الغثيان، أو الخفقان).<br />&middot;&nbsp;إذا كنت تتناول أو تناولت مؤخراً أدوية تبطئ من معدل ضربات القلب (مثل: حاصرات بيتا، أو فيراباميل، أو ديلتيازيم أو إيفابرادين، أو ديجوكسين، أو عوامل مضادات الكولين أو بيلوكاربين).<br />&middot;&nbsp;إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو الإغماء.<br />&middot;&nbsp;إذا كنت تخطط للتطعيم.<br />&middot;&nbsp;إذا لم تكن قد أصبت بجدري الماء من قبل.<br />&middot;&nbsp;إذا كنت تعاني أو عانيت سابقاً من اضطرابات بصرية أو من علامات تورم أخرى في منطقة الرؤية المركزية في الجزء الخلفي من العين (حالة تعرف باسم وذمة البقعة الصفراء، انظر أدناه)، أو إلتهاب أو عدوى في<br />العين (إلتهاب القزحي)(، أو إذا كنت تعاني من مرض السكري (والذي يمكن أن يسبب مشاكل في العين).<br />&middot;&nbsp;إذا كان لديك مشاكل في الكبد.<br />&middot;&nbsp;إذا كنت تعاني من ارتفاع ضغط الدم الذي لا يمكن التحكم به عن طريق الأدوية.<br />&middot;&nbsp;إذا كنت تعاني من مشاكل شديدة في الرئة أو سعال نتيجة التدخين.<br />إذا انطبق عليك أي مما سبق ذكره أو كنت غير متأكد، تحدث إلى طبيبك قبل تناول فيجويا.<br />تباطؤ معدل ضربات القلب وعدم انتظام ضربات القلب في بداية العلاج أو بعد تناول الجرعة الأولى من 0.5&nbsp;ملجم عند التبديل من جرعة يومية من 0.25 ملجم، يسبب&nbsp; فينجوليمود إبطاء في معدل ضربات القلب.<br />نتيجة لذلك، قد تشعر بالدوخة أو التعب، أو تشعر حسياً بضربات قلبك، أو قد ينخفض ضغط الدم لديك. إذا كانت هذه الآثار شديدة، أخبر طبيبك، لأنك قد تحتاج إلى علاج على الفور.<br />يمكن أن يسبب فينجوليمود أيضاً عدم انتظام ضربات القلب، وخاصة بعد الجرعة الأولى. عادة ما يعود نبض القلب غير المنتظم إلى طبيعته في أقل من يوم واحد. عادة ما تعود معدل ضربات القلب البطيئة إلى طبيعتها خلال شهر واحد. خلال هذه الفترة، لا يتوقع عادة حدوث آثار سريرية ملحوظة على معدل ضربات القلب.<br />سوف يطلب منك طبيبك البقاء في غرفة الجراحة أو العيادة لمدة 6 ساعات على الأقل، لفحص النبض وضغط الدم لديك كل ساعة، بعد تناول الجرعة الأولى من فينجوليمود أو بعد تناول الجرعة الأولى من 0.5&nbsp;ملجم عند التبديل من جرعة يومية من 0.25&nbsp;ملجم، بحيث يمكن اتخاذ التدابير المناسبة في حالة حدوث آثار جانبية&nbsp;في بداية العلاج.</p><p>يجب إجراء مخطط كهربية القلب قبل الجرعة الأولى من فينجوليمود وبعد فترة المراقبة لمدة 6 ساعات.</p><p>قد&nbsp;يراقب طبيبك مخطط كهربية القلب بشكل مستمر خلال ذلك الوقت. إذا كان لديك تباطؤ شديد أو نقص في معدل ضربات القلب بعد فترة 6 ساعات، أو إذا ظهر خلل في مخطط كهربية القلب لديك، فقد تحتاج إلى المراقبة لفترة أطول (ساعتان إضافيتان على الأقل وربما طوال الليل)&nbsp;حتى يتم زوال تلك الأعراض. قد ينطبق الشيء نفسه إذا كنت تستأنف تناول فينجوليمود بعد فترة انقطاع عن العلاج، وهذا يتوقف على كل من فترة الانقطاع عن العلاج وطول المدة التي كنت تتناول فيها فينجوليمود قبل الانقطاع عن العلاج.</p><p>إذا كان لديك، أو إذا كنت في خطر التعرض إلى وجود خلل أو عدم انتظام في ضربات القلب، أو لديك خلل في مخطط كهربية القلب، أو إذا كان لديك مرض بالقلب أو فشل بالقلب، فقد لا يكون فينجوليمود مناسباً لك. إذا كان لديك تاريخ من فقدان الوعي المفاجئ أو انخفاض في معدل ضربات القلب، فقد لا يكون فينجوليمود مناسباً لك. سيتم تقييمك من قبل أخصائي أمراض القلب لتقديم المشورة حول كيفية بدء العلاج بفينجوليمود، بما في ذلك المراقبة الليلية.</p><p>إذا كنت تتناول أدوية يمكن أن تؤدي إلى انخفاض معدل ضربات القلب، فقد لا يكون فينجوليمود مناسباً لك. سوف تحتاج إلى أن يتم تقييمك من قبل أخصائي أمراض القلب، والذي سيتحقق مما إذا كان من الممكن تحويلك إلى دواء بديل لا يقلل من معدل ضربات القلب لديك من أجل السماح بالعلاج بفينجوليمود. إذا كان مثل هذا التبديل مستحيلاً، فسوف ينصحك أخصائي القلب بكيفية بدء العلاج بفينجوليمود، بما في ذلك المراقبة الليلية.</p><p>إذا لم تكن قد أصبت بجدري الماء من قبل<br />إذا لم تكن قد أصبت بجدري الماء من قبل، فسوف يفحص طبيبك مناعتك ضد الفيروس الذي يسببه (فيروس الحماق النطاقي). إذا لم تكن محمي ضد الفيروس، فقد تحتاج إلى التطعيم قبل بدء العلاج بفيجويا. إذا كانت هذه هي الحالة، فسيقوم طبيبك بتأخير بدء العلاج بفيجويا لمدة شهر واحد بعد اكتمال الدورة الكاملة للتطعيم.</p><p>تم الإبلاغ عن الإصابة بعدوى فيروس الورم الحليمي البشري، ويشمل الورم الحليمي، خلل التنسج، الثآليل والسرطان المرتبط بفيروس الورم الحليمي البشري، في المرضى الخاضعين للعلاج بفينجوليمود. سوف يفكر طبيبك فيما إذا كنت بحاجة إلى التطعيم ضد فيروس الورم الحليمي البشري قبل بدء العلاج. إذا كنتِ امرأة، سيوصي طبيبك أيضاً بفحص فيروس الورم الحليمي البشري.</p><p>وذمة البقعة الصفراء<br />قبل أن تبدأ في تناول فيجويا، إذا كان لديك أو كنت تعاني من اضطرابات بصرية أو علامات تورم أخرى في منطقة الرؤية المركزية في الجزء الخلفي من العين، أو إلتهاب أو عدوى في العين (إلتهاب القزحية)&nbsp;أو مرض<br />السكري، فقد يرغب طبيبك في إجراء فحص لعينيك.</p><p>قد يطلب منك طبيبك إجراء فحص للعين خلال 3 إلى 4 أشهر بعد بدء العلاج بفيجويا.&nbsp;<br />البقعة هي منطقة صغيرة من شبكية العين في الجزء الخلفي من العين، والتي تمكنك من رؤية الأشكال، والألوان، والتفاصيل بوضوح وبشكل حاد. قد يسبب فيجويا تورم في البقعة، وهي حالة تعرف باسم وذمة البقعة الصفراء. يحدث التورم عادة في الأشهر الأربعة الأولى من فترة العلاج بفيجويا.<br />فرصتك للتعرض إلى حدوث الوذمة البقعية تزداد إذا كنت تعاني من مرض السكري أو إذا كنت مصاباً بإلتهاب بالعين يسمى إلتهاب القزحية. في هذه الحالات سيرغب طبيبك في إجراء فحوصات لعينيك بشكل منتظم للكشف عن وذمة البقعة الصفراء.</p><p>إذا كنت تعاني من الوذمة البقعية، فتحدث إلى طبيبك قبل أن تستأنف العلاج بفيجويا.<br />يمكن أن تسبب الوذمة البقعية بعض الأعراض الخاصة بالرؤية والتي تشبه تلك الخاصة بنوبة التصلب العصبي المتعدد (إلتهاب العصب البصري). في وقت مبكر، قد لا يكون هناك أي أعراض. تأكد من إخبار طبيبك عن أي تغييرات في رؤيتك. قد يرغب طبيبك في إجراء فحوصات لعينيك، خاصة إذا:<br />&middot; كان هناك ضبابية أو ظلال في مركز الرؤية.<br />&middot; تعرضت لوجود بقعة عمياء في مركز رؤيتك.<br />&middot; كانت لديك مشاكل في رؤية الألوان أو التفاصيل الدقيقة.</p><p>اختبارات وظائف الكبد<br />إذا كنت تعاني من مشاكل شديدة في الكبد، يجب ألا تتناول فيجويا. قد يؤثر فيجويا على وظائف الكبد. من المحتمل ألا تلاحظ أي أعراض، لكن إذا لاحظت اصفرار جلدك أو اصفرار بياض عينيك، أو بول غامق بشكل غير طبيعي(بني اللون)، أو ألم في الجانب الأيمن من منطقة المعدة (البطن)، أو التعب، أو الشعور بجوع أقل أو غثيان وقيء غير مبرر، أخبر طبيبك على الفور.<br />إذا شعرت بأي من هذه الأعراض بعد بدء تناول فيجويا، أخبر طبيبك على الفور.<br />قبل العلاج وأثناءه وبعده، سيطلب طبيبك إجراء فحوصات دم لمراقبة وظائف الكبد. إذا كانت نتائج الاختبار تشير إلى وجود مشكلة في الكبد، فقد تضطر إلى إيقاف العلاج بفيجويا.</p><p>ارتفاع ضغط الدم<br />نظرًا لأن فيجويا يسبب ارتفاعاً طفيفاً في ضغط الدم، فقد يرغب طبيبك في فحص ضغط الدم لديك بانتظام.<br />مشاكل الرئة<br />فيجويا له تأثير طفيف على وظيفة الرئة. قد يكون لدى المرضى الذين يعانون من مشاكل شديدة بالرئة أو لديهم سعال نتيجة التدخين فرصة أكبر للإصابة بآثار جانبية.<br />تعداد الدم<br />التأثير المطلوب بعلاج فيجويا هو تقليل كمية خلايا الدم البيضاء في دمك. هذا عادة ما يعود إلى طبيعته خلال شهرين من التوقف عن العلاج. إذا كنت بحاجة إلى إجراء أي اختبارات دم، أخبر الطبيب بأنك تتناول فيجويا.<br />خلاف ذلك، قد لا يكون من الممكن للطبيب أن يفهم نتائج الاختبار، وفي أنواع معينة من اختبار الدم قد يحتاج طبيبك إلى أخذ المزيد من الدم بشكل أكثر من المعتاد.<br />قبل أن تبدأ في تناول فيجويا، سيؤكد طبيبك ما إذا كان لديك ما يكفي من خلايا الدم البيضاء في دمك وقد ترغب في تكرار الفحص بانتظام. في حال لم يكن لديك ما يكفي من خلايا الدم البيضاء، قد تضطر إلى إيقاف<br />العلاج بفيجويا.<br />متلازمة اعتلال الدماغ الخلفي القابل للانعكاس<br />نادراً ما تم الإبلاغ عن حالة تسمى متلازمة اعتلال الدماغ الخلفي القابل للانعكاس لدى مرضى التصلب العصبي المتعدد الخاضعين للعلاج بفينجوليمود.<br />قد تشمل الأعراض ظهور مفاجئ لصداع شديد، ارتباك، نوبات صرع وتغير في الرؤية. أخبر طبيبك على الفور إذا كنت تعاني من أي من هذه الأعراض أثناء علاجك بفيجويا، لأنها قد تكون خطيرة.<br />السرطان<br />تم الإبلاغ عن سرطان الجلد في مرضى التصلب العصبي المتعدد الخاضعين للعلاج بفينجوليمود. تحدث إلى طبيبك على الفور إذا لاحظت أي عقيدات جلدية (مثل: عقيدات لؤلؤية لامعة)، أو بقع أو تقرحات مفتوحة لا تلتئم خلال أسابيع. قد تتضمن أعراض سرطان الجلد نمو غير طبيعي أو تغيرات في أنسجة الجلد (مثل: الشامات غير العادية) مع تغير اللون، أو الشكل أو الحجم مع مرور الوقت. قبل أن تبدأ في تناول فيجويا، يجب<br />إجراء فحص للجلد للتحقق مما إذا كان لديك أي عقيدات جلدية. سيقوم طبيبك أيضاً بإجراء فحوصات جلدية بشكل منتظم أثناء علاجك بفيجويا. إذا كنت تعاني من مشاكل في جلدك، فقد يحولك طبيبك إلى طبيب أمراض<br />جلدية، والذي قد يقرر بعد التشاور أنه من المهم أن يتم رؤيتك بشكل منتظم.<br />تم الإبلاغ عن نوع من سرطان الجهاز الليمفاوي (سرطان الغدد الليمفاوية) في مرضى التصلب العصبي<br />المتعدد الذين خضعوا للعلاج بفينجوليمود.<br />التعرض لأشعة الشمس والحماية من أشعة الشمس<br />يضعف فيجويا نظام المناعة لديك. هذا يزيد من خطر الإصابة بالسرطانات، خاصة سرطانات الجلد. يجب عليك<br />الحد من التعرض لأشعة الشمس والأشعة فوق البنفسجية عن طريق:<br />&middot; ارتداء ملابس واقية مناسبة.<br />&middot; استخدام بشكل منتظم المستحضرات الواقية من الشمس ذات درجة عالية من الحماية من الأشعة فوق البنفسجية.<br />آفات الدماغ غير العادية المرتبطة بانتكاس مرض التصلب العصبي المتعدد<br />تم الإبلاغ عن حالات نادرة من آفات الدماغ الكبيرة بشكل غير عادي المرتبطة بانتكاس مرض التصلب العصبي المتعدد في المرضى الذين خضعوا للعلاج بفينجوليمود. في حالة الانتكاس الشديد، سينظر طبيبك في إجراء التصوير بالرنين المغناطيسي لتقييم هذه الحالة وسيقرر ما إذا كنت بحاجة إلى التوقف عن تناول فيجويا.</p><p>التبديل من العلاجات الأخرى إلى فيجويا<br />قد يحولك طبيبك مباشرة من بيتا إنترفيرون، أو أسيتات الجلاتيرامر أو ثنائي ميثيل فومارات إلى فينجوليمود إذا لم تكن هناك علامات على وجود تشوهات ناتجة عن علاجك السابق. قد يضطر طبيبك إلى إجراء فحص دم لاستبعاد مثل هذه التشوهات. بعد إيقاف ناتاليزوماب، قد تضطر إلى الانتظار لمدة 2-3 أشهر قبل بدء&nbsp;العلاج بفيجويا. للتبديل من تيريفلونومايد، قد ينصحك طبيبك بالانتظار لفترة معينة أو الخضوع لإجراء سريع<br />للإزالة. إذا تم علاجك باستخدام أليمتوزوماب، فيجب إجراء تقييم شامل ومناقشة مع طبيبك لتقرير ما إذا كان فيجويا مناسبًا لك.<br />النساء في سن الإنجاب<br />إذا تم استخدامه أثناء الحمل، يمكن أن يسبب فيجويا الضرر للجنين. قبل أن تبدأ العلاج بفيجويا، سوف يشرح طبيبك المخاطر لك ويطلب منك إجراء اختبار الحمل للتأكد من أنك لست حاملاً. سوف يعطيك طبيبك بطاقة تشرح سبب عدم إمكانية الحمل أثناء تناول فيجويا. تشرح أيضاً ما يجب عليكِ فعله لتجنب الحمل أثناء تناول فيجويا. يجب عليكِ استخدام وسائل منع الحمل الفعّالة أثناء العلاج ولمدة شهرين بعد التوقف عن العلاج (انظر&nbsp; قسم &quot;الحمل والرضاعة&quot;).</p><p>تفاقم مرض التصلب العصبي المتعدد بعد التوقف عن العلاج بفيجويا لا تتوقف عن تناول فيجويا أو تغير جرعتك دون التحدث إلى طبيبك أولاً.<br />أخبر طبيبك على الفور إذا كنت تعتقد أن مرض التصلب العصبي المتعدد لديك يزداد سوءًا بعد أن توقفت<br />، عن العلاج بفيجويا. قد يكون هذا خطيراً (انظر &quot;إذا توقفت عن تناول فيجويا&quot; في القسم 3 ، وكذلك القسم 4<br />&quot;الآثار الجانبية المحتملة&quot;).</p><p><strong>كبار السن</strong><br />المعلومات بشأن استخدام فينجوليمود في المرضى المسنين (أكثر من 65 عاماً) محدودة. تحدث إلى طبيبك&nbsp;<br />إذا كانت لديك أي مخاوف.<br /><strong>الأطفال والمراهقون</strong><br />لا يستخدم فينجوليمود للأطفال دون سن 10 سنوات لأنه لم تتم دراسته في مرضى التصلب العصبي المتعدد&nbsp;<br />في هذه الفئة العمرية.<br />تنطبق الاحتياطات والتحذيرات المذكورة أعلاه أيضاً على الأطفال والمراهقين. المعلومات التالية مهمة بشكل<br />خاص للأطفال والمراهقين ومقدمي الرعاية لهم:<br />&middot; قبل أن تبدأ في تناول فيجويا، سيفحص طبيبك حالة التطعيم لديك. إذا لم تكن قد تلقيت بعض المطاعيم، فقد<br />يكون من الضروري إعطاؤك هذه المطاعيم قبل البدء في العلاج بفيجويا.<br />&middot;&nbsp;في المرة الأولى التي تتناول فيها فينجوليمود، أو عند التبديل من جرعة يومية من 0.25 ملجم إلى جرعة&nbsp;<br />يومية من 0.5 ملجم، سيقوم طبيبك بمراقبة معدل ضربات القلب ونبضات القلب (انظر أعلاه &quot;تباطؤ معدل<br />ضربات القلب وعدم انتظام ضربات القلب&quot;).<br />&middot;&nbsp;إذا كنت تعاني من تشنجات أو نوبات قبل أو أثناء تناول فيجويا، أخبر طبيبك.<br />&middot;&nbsp;إذا كنت تعاني من الاكتئاب أو القلق أو إذا أصبت بالاكتئاب أو القلق أثناء تناولك فيجويا، فأخبر طبيبك. قد<br />تحتاج إلى المزيد من المراقبة عن قرب.</p><p><strong>الأدوية الأخرى وفيجويا</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. أخبر طبيبك إذا كنت<br />تتناول أي من الأدوية التالية:<br />&middot;&nbsp;الأدوية التي تثبط أو تعدل استجابة الجهاز المناعي، بما في ذلك الأدوية الأخرى المستخدمة لعلاج مرض<br />التصلب العصبي المتعدد، مثل: بيتا إنترفيرون، أسيتات الجلاتيرامر، ناتاليزوماب، ميتوكسانترون،<br />تيريفلونومايد، ثنائي ميثيل فومارات أو أليمتوزوماب. يجب عدم استخدام فيجويا بالتزامن مع مثل هذه الأدوية<br />حيث قد يؤدي ذلك إلى زيادة التأثير على جهاز المناعة (انظر أيضاً &quot;لا تتناول فيجويا&quot;).<br />&middot;&nbsp;الستيرويدات القشرية، بسبب التأثير الإضافي المحتمل على الجهاز المناعي.<br />&middot;&nbsp;المطاعيم. إذا كنت بحاجة إلى تلقي مطعوم، فاطلب نصيحة طبيبك أولاً. خلال فترة العلاج بفيجويا ولمدة<br />تصل إلى شهرين بعد العلاج، يجب ألا تتلقى أنواعاً معينة من المطاعيم (المطاعيم الحية الموهنة) لأنها قد<br />تؤدي إلى الإصابة بالعدوى التي كان من المفترض أن تمنعها. قد لا تعمل المطاعيم الأخرى كالمعتاد إذا<br />أعطيت خلال هذه الفترة.<br />&middot;&nbsp;الأدوية التي تبطئ نبضات القلب (على سبيل المثال حاصرات بيتا، مثل: أتينولول). قد يؤدي استخدام فيجويا<br />مع هذه الأدوية إلى إلى زيادة التأثير على ضربات القلب في الأيام الأولى بعد بدء العلاج بفيجويا.<br />&middot;&nbsp;أدوية علاج عدم انتظام ضربات القلب، مثل: كينيدين، أو ديسوبيراميد، أو أميودارون أو سوتالول. يجب عدم<br />استخدام فيجويا إذا كنت تستخدم مثل هذه الأدوية حيث قد يزيد ذلك من التأثير على عدم انتظام ضربات القلب<br />(انظر أيضاً &quot;لا تتناول فيجويا&quot;).<br />&middot;&nbsp;الأدوية الأخرى:<br />-&nbsp;مثبطات الأنزيم البروتيني، مضادات الفطريات مثل: كيتوكونازول، مضادات الفطريات من مجموعة<br />الآزول، كلاريثروميسين أو تيليثروميسين.<br />-&nbsp;كاربامازيبين، ريفامبيسين، فينوباربيتال، فينيتوين، إيفافايرينز أو نبتة سانت جون (وذلك لوجود خطر<br />محتمل لتقليل فعالية فيجويا).<br /><strong>الحمل والرضاعة</strong><br />إذا كنت حاملاً أو مرضعة، تعتقدين بأنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة<br />قبل تناول هذا الدواء.<br />الحمل<br />لا تستخدمي فيجويا أثناء الحمل، إذا كنت تحاولين الإنجاب أو إذا كنت امرأة يمكن أن تصبحي حاملاً ولا<br />تستخدمين وسيلة فعّالة لمنع الحمل. إذا تم استخدام فيجويا أثناء الحمل، فهناك خطر حدوث ضرر على الجنين.<br />معدل التشوهات الخلقية التي لوحظت عند الأطفال الذين خضعوا للعلاج بفينجوليمود أثناء الحمل حوالي ضعف<br />المعدل الملاحظ في عموم السكان (الذين يبلغ معدل التشوهات الخلقية فيها حوالي 2-3%). تضمنت التشوهات&nbsp;<br />الأكثر شيوعاً التي تم الإبلاغ عنها: التشوهات القلبية، والكلوية، والعضلية الهيكلية.<br />لذلك، إذا كنتِ امرأة في سن الإنجاب:<br />&middot;&nbsp;قبل بدء العلاج بفيجويا، سيخبركِ طبيبك عن المخاطر التي سيتعرض لها الجنين ويطلب منكِ إجراء اختبار<br />الحمل للتأكد من أنكِ لست حاملاً، و،<br />&middot;&nbsp;يجب استخدام وسيلة فعّالة لمنع الحمل أثناء تناول فيجويا ولمدة شهرين بعد التوقف عن تناوله لتجنب الحمل.<br />تحدثي مع طبيبك حول الطرق الموثوقة لمنع الحمل.<br />سوف يعطيكِ طبيبك بطاقة تشرح سبب عدم إمكانية الحمل أثناء تناول فيجويا.<br />إذا أصبحتِ حاملاً أثناء تناول فيجويا، أخبري طبيبك على الفور. سيقرر طبيبك إيقاف العلاج (انظري &quot;إذا<br />توقفت عن تناول فيجويا&quot; في القسم3 ، وكذلك في القسم 4، &quot;الآثار الجانبية المحتملة&quot;). سيتم إجراء مراقبة&nbsp;<br />متخصصة قبل الولادة.<br />الرضاعة<br />يجب ألا ترضعي أثناء تناول فيجويا.<br />يمكن أن ينتقل فيجويا إلى حليب الثدي وهناك خطر حدوث آثار جانبية خطيرة على الطفل.<br /><strong>القيادة واستخدام الآلات</strong><br />سيخبرك طبيبك ما إذا كانت حالتك المرضية تؤهلك لقيادة المركبات، بما في ذلك الدراجة، واستخدام الآلات<br />بأمان. ليس من المتوقع أن يكون فيجويا ذو تأثير على قدرتك على القيادة واستخدام الآلات.<br />ومع ذلك، عند بدء العلاج، يجب عليك البقاء في غرفة الجراحة أو العيادة لمدة 6 ساعات بعد تناول الجرعة<br />الأولى من فيجويا. قد تتأثر قدرتك على القيادة واستخدام الآلات خلال هذه الفترة الزمنية وربما بعدها.<br /><strong>يحتوي فيجويا على كبريتات لوريل الصوديوم</strong><br />يحتوي هذا الدواء على أقل من1 مليمول صوديوم ( 23 ملجم) لكل كبسولة، وهذا يعني بشكل أساسي أنه&nbsp;<br />&lsquo;خالٍ من الصوديوم&rsquo;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتم الإشراف على العلاج بفيجويا من قبل طبيب من ذوي الخبرة في عالج مرض التصلب المتعدد.</p><p>قم دائما&nbsp;بتناول هذا الدواء تماما&nbsp;كما أخبرك طبيبك. تحقق من طبيبك إذا لم تكن متأكدا.</p><p>الجرعة الموصى بها هي:</p><p>البالغين:</p><p>الجرعة هي كبسولة واحدة من 0.5 ملجم في اليوم.</p><p>الأطفال&nbsp;والمراهقون (10 سنوات من العمر ومافوق):</p><p>تعتمد الجرعة على وزن الجسم:</p><p>الأطفال والمراهقون الذين يساوي وزن جسمهم أو يقل عن 40 كلجم: كبسولة واحدة من 0.25 ملجم في اليوم.</p><p>فينجوليمود 0.5 ملجم كبسوالت صلبة ليست مناسبة لمرضى الأطفال&nbsp;الذين تبلغ أوزانهم <strong>&le;</strong> 40 كلجم.</p><p>المستحضرات الطبية الأخرى&nbsp;المحتوية على فينجوليمود متوفرة بتركيز أقل (على شكل كبسولات من 0.25 ملجم).</p><p>الأطفال&nbsp; والمراهقون الذين تزيد أوزانهم عن 40 كلجم: كبسولة واحدة من 0.5 ملجم في اليوم.</p><p>الأطفال والمراهقون الذين يبدأون تناول كبسولة واحدة من 0.25 ملجم يوميا&nbsp;ثم يصلون بعد ذلك إلى وزن ثابت</p><p>يزيد عن 40 كلجم، سيوجههم الطبيب للتبديل إلى كبسولة واحدة من 0.5 ملجم يوميا.في هذه الحالة، يوصى&nbsp;بتكرار فترة مراقبة الجرعة الأولى.</p><p>لا تتجاوز الجرعة الموصى بها.</p><p>فيجويا هو للاستخدام عن طريق الفم.</p><p>قم بتناول فيجويا مرة واحدة في اليوم مع كوب من الماء.</p><p>يجب دائما ابتلاع فيجويا كبسولات صلبة بشكل سليم، دون فتحها. يمكن تناول فيجويا مع أو بدون الطعام.</p><p>سيساعدك تناول فيجويا في نفس الوقت كل يوم على تذكر موعد تناول الدواء. إذا كانت لديك أسئلة حول المدة</p><p>التي يجب أن تتناول فيها فيجويا،فتحدث إلى طبيبك أو الصيدلي.</p><p><strong>إذا تناولت فيجويا أكثر من الالزم</strong></p><p>إذا تناولت الكثير من فيجويا، فاتصل بطبيبك على الفور.</p><p><strong>إذا نسيت تناول فيجويا</strong></p><p>إذا كنت تتناول فيجويا لمدة تقل عن شهر واحد ونسيت تناول جرعة واحدة لمدة يوم كامل، فاتصل بطبيبك قبل</p><p>تناول الجرعة التالية. قد يقرر طبيبك أن يبقيك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية.</p><p>إذا كنت تتناول فيجويا لمدة شهر واحد على الأقل ونسيت تناول عالجك لأكثر من أسبوعين، فاتصل بطبيبك قبل تناول الجرعة التالية.</p><p>قد يقرر طبيبك أن يبقيك تحت الملاحظة في الوقت الذي تتناول فيه الجرعة التالية. ومع ذلك، إذا نسيت تناول علاجك لمدة تصل إلى أسبوعين، فيمكنك تناول الجرعة التالية كما هو مخطط لها.</p><p>لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول فيجويا</strong></p><p>لا تتوقف عن تناول فيجويا أو تغير جرعتك دون التحدث إلى طبيبك أولا.</p><p>سيبقى فيجويا في جسمك لمدة تصل إلى شهرين بعد التوقف عن تناوله. قد يبقى عدد خلايا الدم البيضاء(عدد&nbsp;الخلايا الليمفاوية)</p><p>منخفضا أيضا&nbsp;خلال هذا الوقت وقد تحدث الآثارالجانبية المذكورة في هذه النشرة. بعد إيقاف فيجويا&nbsp;قد تضطر إلى الانتظار لمدة 6-8 أسابيع قبل البدء في علاج&nbsp;جديد لمرض التصلب العصبي المتعدد.</p><p>إذا اضطررت إلى إعادة تناول فيجويا بعد أكثر من أسبوعين من التوقف عن تناوله، فقد يتكرر التأثير على&nbsp;معدل ضربات القلب الذي يظهر بشكل طبيعي عند بدء العلاج لأول&nbsp;مرة وستحتاج إلى المراقبة في غرفة الجراحة أو العيادة لإعادة البدء في العلاج.</p><p>لا تقم بإعادة تناول فيجويا بعد إيقافه لأكثر من أسبوعين دون طلب المشورة من طبيبك.</p><p>سيقرر طبيبك ما إذا كنت بحاجة إلى المراقبة وكيفية ذلك بعد إيقاف فيجويا. أخبر طبيبك على الفور إذا كنت&nbsp;تعتقد أن مرض التصلب العصبي المتعدد لديك يزداد سوءا بعد أن توقفت عن العلاج بفيجويا.قد يكون هذا أمرا خطيرا.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>قد تكون بعض الآثار الجانبية خطيرة أو يمكن أن تصبح خطيرة.</p><p>شائعة (قد تؤثر على ما يصل إلى 1 من 10 أشخاص):</p><p>&middot; سعال مع مخاط، عدم راحة بالصدر، حمى (وهي علامات لوجود اضطراب بالرئة).</p><p>&middot;عدوى فيروس الهربس (القوباء المنطقية أو الهربس النطاقي) مع أعراض مثل تقرحات، وحرق، حكة أو ألم&nbsp;في الجلد،</p><p>عادة على الجزء العلوي من الجسم أو الوجه. قد تكون الأعراض الأخرى هى حمى وضعف في&nbsp;المراحل المبكرة من الأصابة بعدوى، يليها خدران، أو حكة أو بقع حمراء مع ألم شديد.</p><p>&middot;بطء نبضات القلب (بطء القلب)، عدم انتظام ضربات القلب.</p><p>&middot;نوع من سرطان الجلد يسمى سرطان الخلايا القاعدية والذي يظهر غالبا&nbsp;كأنه عقيدات لؤلؤية، على الرغم من&nbsp;أنه يمكن أن يتخذ أشكال أخرى.</p><p>&middot;من المعروف زيادة معدل تكرار الاكتئاب والقلق عند مرضى التصلب العصبي المتعدد كما تم الإبالغ عن&nbsp;ذلك أيضا&nbsp;ً في الأطفال الذين خضعوا للعلاج بفينجوليمود.</p><p>&middot;فقدان الوزن.</p><p>غير شائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص):</p><p>&middot; إلتهاب رئوي مع أعراض مثل: الحمى، والسعال، وصعوبة في التنفس.</p><p>&middot;وذمة البقعة الصفراء (وهي تورم في منطقة الرؤية المركزية للشبكية في الجزء الخلفي من العين) مع&nbsp;أعراض مثل: وجود ظلال أو بقعة عمياء في مركز الرؤية، أو عدم وضوح الرؤية، أو مشاكل في رؤية&nbsp;الألوان أو التفاصيل.</p><p>&middot;انخفاض في الصفائح الدموية مما يزيد من خطر النزيف أو الكدمات.</p><p>&middot;سرطان الجلد الخبيث (نوع من سرطان الجلد الذي عادة ما يتطور من شامة غير عادية).&nbsp;تشمل العلامات المحتملة لسرطان الجلد وجود شامات متغيرة الحجم، أو الشكل، أو الارتفاع، أو اللون مع&nbsp;مرور الوقت، أو ظهور شامات جديدة. قد تكون الشامات مصحوبة بحكة، أو نزف أو تقرح.</p><p>تشنج، نوبات (أكثر تكرارا&nbsp;ً في الأطفال والمراهقين من البالغين).</p><p>نادرة (قد تؤثر على ما يصل إلى 1 من 1000 شخص):</p><p>حالة تسمى متلازمة اعتلال الدماغ الخلفي القابل للانعكاس. قد تشمل الأعراض حدوث مفاجئ لصداع شديد، وارتباك، ونوبات صرع و/أو اضطرابات في الرؤية.</p><p>&middot;سرطان الغدد الليمفاوية (نوع من السرطان يصيب الجهاز الليمفاوي).</p><p>&middot;سرطان الخلايا الحرشفية: نوع من سرطان الجلد الذي قد يظهر كعقدة حمراء صلبة، أو قرحة مع قشرة، أو&nbsp;قرحة جديدة على ندبة موجودة.</p><p><strong>نادرة جدا&nbsp;ً (قد تؤثر على ما يصل إلى 1 من 10000 شخص):</strong></p><p>&middot;خلل في تخطيط القلب الكهربائى(انعكاس الموجة-T).</p><p>&middot;ورم مرتبط بالعدوى بفيروس الهربس البشري 8 (كابوسي ساركوما).</p><p><strong>غير معروفة (لا يمكن تقدير معدل تكرارها من البيانات المتاحة):</strong></p><p>&middot;ردور فعل تحسسية، بما في ذلك أعراض الطفح الجلدي أو الحكة، أو تورم في الشفاه، واللسان أو الوجه،&nbsp;والتي من المرجح أن تحدث في اليوم الذي تبدأ فيه العلاج بفينجوليمود.</p><p>&middot;علامات مرض في الكبد (بما في ذلك فشل الكبد) مثل: اصفرار الجلد أو بياض العينين(اليرقان)، والغثيان&nbsp;أو القيء، وألم في الجانب الأيمن من منطقة المعدة (البطن)، والبول الداكن (لونه بني)، والشعور بجوع أقل&nbsp;من المعتاد، تعب واضطراب في اختبارات وظائف الكبد. في عدد قليل جدا&nbsp;ً من الحالات، يمكن أن يؤدي&nbsp;فشل الكبد إلى زراعة الكبد.</p><p>&middot;خطر حدوث عدوى نادرة في الدماغ تسمى اعتلال بيضاء الدماغ متعدد البؤر التدريجي. قد تتشابه أعراض&nbsp;اعتلال بيضاء الدماغ متعدد البؤر التدريجي مع أعراض انتكاس مرض التصلب العصبي المتعدد. قد تظهرً أعراض قد لا تدركها بنفسك، مثل: التغيرات في الحالة المزاجية أو السلوك، أو فقدان الذاكرة، أو&nbsp;صعوبات في النطق والتواصل، والتي قد تحتاج لمزيد من البحث من قبل طبيبك لاستبعاد اعتلال بيضاء&nbsp;الدماغ متعدد البؤر التدريجي. لذلك، إذا كنت تعتقد أن مرض التصلب</p><p>العصبي المتعدد لديك يزداد سوءا أو&nbsp;إذا لاحظت أنت أو الأشخاص المقربون منك أي أعراض جديدة أو غير عادية، فمن المهم جدا&nbsp;ن تتحدث إلى&nbsp;طبيبك في أقرب وقت ممكن.&nbsp;</p><p>&middot;إلتهابات المكورات العقدية (نوع من العدوى الفطرية)، بما في ذلك إلتهاب السحايا بالمكورات العقدية مع&nbsp;وجود أعراض مثل: الصداع المصحوب بتصلب شديد في الرقبة، وحساسية للضوء، والغثيان و/أو الارتباك.على الوجه، أو الرأس أو الرقبة. سرطان خلايا ميركل يمكن أن يظهر أيضا</p><p>&middot;سرطان خلايا ميركل (نوع من سرطان الجلد).</p><p>العلامات المحتملة لسرطان خلايا ميركل تشمل عقيدة بلون اللحم أو بلون أحمر مزرق، غير مؤلمة، غالبا&nbsp;على الوجه، أو الرأس أو الرقبة. سرطان خلايا ميركل يمكن أن يظهر أيضا&nbsp;ً كعقدة أو كتلة غير مؤلمة. التعرض لفترة طويلة لأشعة الشمس مع ضعف في الجهاز المناعي قد يؤثر على خطر الإصابة بسرطان خلايا ميركل.</p><p>&middot;بعد توقف العالج بفينجوليمود، يمكن أن تعود أعراض مرض التصلب العصبي المتعدد وقد تصبح أسوأ مما كانت عليه قبل أو أثناء العلاج.</p><p>&middot;شكل من أشكال فقر الدم المناعي الذاتي (انخفاض كمية خلايا الدم الحمراء) حيث يتم تدمير خلايا الدم الحمراء (فقر الدم الانحلالي المناعي الذاتي).</p><p>إذا واجهت أيا&nbsp;ً من هذه الأعراض، فأخبر طبيبك على الفور.</p><p><strong>آثار جانبية أخرى</strong></p><p>شائعة جدا&nbsp;ً (قد تؤثر على ما يصل إلى أكثر من 1 من 10 أشخاص):</p><p>&middot;العدوى بفيروس الإنفلونزا مع أعراض مثل: التعب، والقشعريرة، وإلتهاب الحلق، وآلام في المفاصل أو العضلات، مع وجود حمى.</p><p>&middot;الشعور بضغط أو ألم في الخدين والجبهة (إلتهاب الجيوب الأنفية).</p><p>&middot;صداع في الرأس.</p><p>&middot;إسهال.</p><p>&middot;ألم في الظهر.</p><p>&middot;ارتفاع مستويات إنزيمات الكبد والتي تتضح من خلال اختبار الدم.</p><p>&middot;السعال.</p><p><strong>شائعة (قد تؤثر على ما يصل إلى 1 من 10 أشخاص):</strong></p><p>&middot;داء السعفة، وهو إلتهاب فطري في الجلد (سعفة متعددةالألوان).</p><p>&middot;دوخة.</p><p>&middot;صداع شديد غالبا&nbsp;ً ما يكون مصحوبا&nbsp;ً بغثيان، وقيء وحساسية للضوء (صداع نصفي).</p><p>&middot;انخفاض مستوى خلايا الدم البيضاء (الخلايا الليمفاوية، الكريات البيض).</p><p>&middot;ضعف.</p><p>&middot;طفح جلدي مصحوب باحمرار، وألم يشبه الحرق، مع وجود حكة (إكزيما).</p><p>&middot;حكة.</p><p>&middot;ارتفاع مستوى الدهون الثلاثية بالدم.</p><p>&middot;تساقط الشعر.</p><p>&middot;انقطاع النفس.</p><p>&middot;اكتئاب.</p><p>&middot;عدم وضوح الرؤية (انظر أيضا&nbsp;ً القسم الخاص بوذمة البقعة الصفراء تحت عنوان &quot;قد تكون بعض الآثار&nbsp;الجانبية خطيرة أو يمكن أن تصبح خطيرة&quot;).</p><p>&middot;ارتفاع ضغط الدم(قد يسبب فينجوليمود زيادة طفيفة في ضغط الدم).</p><p>&middot;ألم في العضلات.</p><p>&middot;ألم في المفاصل.</p><p><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من 100 شخص):</strong></p><p>&middot;انخفاض مستوى نوع معين من خلايا الدم البيضاء (العدلات).</p><p>&middot;اكتئاب المزاج.</p><p>&middot;غثيان.</p><p><strong>نادرة (قد تؤثر على ما يصل إلى 1 من 1000 شخص):</strong></p><p>&middot;سرطان الجهاز الليمفاوي (سرطان الغدد الليمفاوية)</p><p><strong>غير معروفة (لا يمكن تقدير معدل تكرارها من البيانات المتاحة):</strong></p><p>&middot;تورم في الأطراف.</p><p>إذا تعرضت لتأثير أي مما سبق بشدة، أخبر طبيبك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ظروف تخزين فيجويا</strong></p><p>احفظ هذا الدواء بعيدا&nbsp;ً عن مرأى ومتناول الأطفال.</p><p>يحفظ في درجة حرارة أقل من&deg;30 مئوية.</p><p>يحفظ بالعبوة الأصلية للحماية من الرطوبة.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء&nbsp;الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>لا تستخدم أي عبوة تالفة أو تظهر عليها علامات العبث.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص&nbsp;من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي محتويات فيجويا&nbsp;</strong></p><p>المادة الفعالة هي فينجوليمود.</p><p>تحتوي كل كبسولة صلبة على 0.5 ملجم فينجوليمود(على هيئة هيدروكلوريد).</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي: محتوى الكبسولة: بيتاسيكلودكسترين وستيرات المغنيسيوم. غلاف الكبسولة: أكسيد الحديد الأصفر، ثاني أكسيد التيتانيوم، جيلاتين وكبريتات لوريل الصوديوم. حبر الطباعة: شيلاك، أكسيد الحديد الأسود وهيدروكسيد البوتاسيوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هو شكل فيجويا ووصفه ومحتويات العبوة</strong></p><p>فيجويا 0.5 ملجم كبسولات صلبة هو مسحوق لونه ما بين الأبيض والمائل إلى الأبيض معبأ في كبسولات جيلاتينية صلبة بحجم ʹ3ʹ مع غطاء للكبسولة بلون أصفر غامق معتم مطبوع عليه &rsquo;FGM &rsquo;بحبر أسود وجسم الكبسولة بلون أبيض معتم مطبوع عليه ʹ0.5mg&nbsp;ʹبحبر أسود. حجم العبوة: 28 كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong></p><p>مصنع شركة الرازي للصناعات الدوائية، المدينة الصناعية الثانية، شارع رقم ،67 تقاطع ،110 صندوق بريد ،3992 الدمام، المملكة العربية السعودية هاتف: 8281919 13 ،966+</p><p>فاكس: 8281313 13 ،966+</p><p>البريد الإلكتروني : info@alrazi-pharma.com&nbsp;</p><p>الموقع الإلكتروني:&nbsp;www.alrazi-pharma.com</p><p><strong>الشركة المصنعة</strong></p><p>مختبرات الدكتور ريدي المحدودة،</p><p>العمليات الفنية للتركيب الصيدلاني،</p><p>وحدة ،7 من 1P إلى 9P ومن 1Q إلى 5Q، مرحلة 3،</p><p>منطقة ڤيساخاباتنام الاقتصادية الخاصة، دوڤادا فيساخاباتنام،</p><p>أندرا براديش، 046 ،530</p><p>الهند.</p><p><strong>للإبلاغ عن الآثار الجانبية</strong></p><p>تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم&nbsp;ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار&nbsp;مباشرة (انظر التفاصيل المذكورة أدناه). من خلال&nbsp;الإبلاغ عن الآثار&nbsp;الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p>&bull;المملكة العربية السعودية</p><p>المركز الوطني للتيقظ الدوائي</p><p>مركز الاتصال الموحد: 19999</p><p>البريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa</p><p>الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p><p>&bull;دول الخليج العربي الأخرى</p><p>الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2022/11؛ رقم النسخة 1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Figoya 0.5 mg Hard Capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 0.5 mg fingolimod (as hydrochloride).
Excipients with known effect: Each hard capsule contains 0.04 mg sodium lauryl sulphate.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Capsules.
White to off-white powder filled in size '3' hard gelatin capsules with dark yellow opaque 
colored cap imprinted 'FGM' with black ink and white opaque colored body imprinted '0.5mg' 
with black ink.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fingolimod is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:</p><p>&bull; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).</p><p>Or</p><p>&bull; Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment should be initiated and supervised by a physician experienced in multiple sclerosis.</p><p><strong><u>Posology </u></strong></p><p>In adults, the recommended dose of fingolimod is one 0.5 mg capsule taken orally once daily.</p><p>In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight:</p><p>&bull; Paediatric patients with body weight &le;40 kg: one 0.25 mg capsule taken orally once daily. Fingolimod 0.5 mg hard capsules are not suitable for paediatric patients with body weight &le;40 kg. Other fingolimod-containing medicinal products are available in a lower strength (as 0.25 mg capsules).</p><p>&bull; Paediatric patients with body weight &gt;40 kg: one 0.5 mg capsule taken orally once daily. Paediatric patients who start on 0.25 mg capsules and subsequently reach a stable body weight above 40 kg should be switched to 0.5 mg capsules.</p><p>When switching from a 0.25 mg to a 0.5 mg daily dose, it is recommended to repeat the same first dose monitoring as for treatment initiation.</p><p>The same first dose monitoring as for treatment initiation is recommended when treatment is interrupted for:</p><p>&bull; 1 day or more during the first 2 weeks of treatment.</p><p>&bull; More than 7 days during weeks 3 and 4 of treatment.</p><p>&bull; More than 2 weeks after one month of treatment.</p><p>if the treatment interruption is of shorter duration than the above, the treatment should be continued with the next dose as planned (see section 4.4).</p><p><u><strong>Special populations</strong></u></p><p>Elderly population</p><p>Fingolimod should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy (see section 5.2).</p><p>Renal impairment</p><p>Fingolimod was not studied in patients with renal impairment in the multiple sclerosis pivotal studies. Based on clinical pharmacology studies, no dose adjustments are needed in patients with mild to severe renal impairment.</p><p>Hepatic impairment</p><p>Fingolimod must not be used in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3). Although no dose adjustments are needed in patients with mild or moderate&nbsp;hepatic impairment, caution should be exercised when initiating treatment in these patients (see sections 4.4 and 5.2).</p><p>Paediatric population</p><p>The safety and efficacy of fingolimod in children aged below 10 years have not yet been established. No data are available.</p><p>There are very limited data available in children between 10&ndash;12 years old (see sections 4.4, 4.8 and 5.1).</p><p><u>Method of administration</u></p><p>This medicinal product is for oral use.</p><p>Fingolimod can be taken with or without food.</p><p>The capsules should always be swallowed intact, without opening them.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Immunodeficiency syndrome.
• Patients with increased risk for opportunistic infections, including immunocompromised 
patients (including those currently receiving immunosuppressive therapies or those 
immunocompromised by prior therapies).
• Severe active infections, active chronic infections (hepatitis, tuberculosis).
• Active malignancies.
• Severe liver impairment (Child-Pugh class C).
• Patients who in the previous 6 months had myocardial infarction (MI), unstable angina 
pectoris, stroke/transient ischaemic attack (TIA), decompensated heart failure (requiring 
inpatient treatment), or New York Heart Association (NYHA) class III/IV heart failure (see 
section 4.4).
• Patients with second-degree Mobitz type II atrioventricular (AV) block or third-degree AV 
block, or sick-sinus syndrome, if they do not wear a pacemaker (see section 4.4).
• Patients with a baseline QTc interval ≥ 500 msec (see section 4.4).
• During pregnancy and in women of childbearing potential not using effective contraception 
(see sections 4.4 and 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Bradyarrhythmia</strong></u></p><p>Initiation of treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays, including the occurrence of isolated reports of transient, spontaneously resolving complete AV block (see sections 4.8 and 5.1).</p><p>After the first dose, the decline in heart rate starts within one hour, and is maximal within 6 hours. This post-dose effect persists over the following days, although usually to a milder extent, and usually abates over the next weeks. With continued administration, the average heart rate returns towards baseline within one month. However individual patients may not return to baseline heart rate by the end of the first month. Conduction abnormalities were typically transient and asymptomatic. They usually did not require treatment and resolved within the first 24 hours on treatment. If necessary, the decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or isoprenaline.</p><p>All patients should have an ECG and blood pressure measurement performed prior to and 6 hours after the first dose of fingolimod. All patients should be monitored for a period of 6 hours for signs and symptoms of bradycardia with hourly heart rate and blood pressure measurement. Continuous (real time) ECG monitoring during this 6 hour period is recommended.</p><p>The same precautions as for the first dose are recommended when patients are switched from the 0.25 mg to the 0.5 mg daily dose.</p><p>Should post-dose bradyarrhythmia-related symptoms occur, appropriate clinical management should be initiated and monitoring should be continued until the symptoms have resolved. Should a patient require pharmacological intervention during the first-dose monitoring, overnight monitoring in a medical facility should be instituted and the first-dose monitoring should be repeated after the second dose of fingolimod.</p><p>If the heart rate at 6 hours is the lowest since the first dose was administered (suggesting that the maximum pharmacodynamic effect on the heart may not yet be manifest), monitoring should be extended by at least 2 hours and until heart rate increases again. Additionally, if after 6 hours, the heart rate is &lt;45 bpm in adults, &lt;55 bpm in paediatric patients aged 12 years and above, or &lt;60 bpm in paediatric patients aged 10 to below 12 years, or the ECG shows new onset second degree or higher grade AV block or a QTc interval &ge;500 msec, extended monitoring (at least overnight monitoring), should be performed, and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring (at least overnight monitoring).</p><p>The effects on heart rate and atrioventricular conduction may recur on re-introduction of fingolimod treatment depending on duration of the interruption and time since start of treatment. The same first dose monitoring as for treatment initiation is recommended when treatment is interrupted (see section 4.2).</p><p>Very rare cases of T-wave inversion have been reported in adult patients treated with fingolimod. In case of T-wave inversion, the prescriber should ensure that there are no associated myocardial ischaemia signs or symptoms. If myocardial ischaemia is suspected, it is recommended to seek advice from a cardiologist.</p><p>Due to the risk of serious rhythm disturbances or significant bradycardia, fingolimod should not be used in patients with sino-atrial heart block, a history of symptomatic bradycardia, recurrent syncope or cardiac arrest, or in patients with significant QT prolongation (QTc&gt;470 msec [adult female], QTc &gt; 460 msec [paediatric female] or &gt;450 msec [adult and paediatric male]), uncontrolled hypertension or severe sleep apnoea (see also section 4.3). In such patients, treatment with fingolimod should be considered only if the anticipated benefits outweigh the potential risks, and advice from a cardiologist sought prior to initiation of treatment in order to determine the most appropriate monitoring. At least overnight extended monitoring is recommended for treatment initiation (see also section 4.5).</p><p>Fingolimod has not been studied in patients with arrhythmias requiring treatment with class Ia (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products. Class Ia and class III antiarrhythmic medicinal products have been associated with cases of torsades de pointes in patients with bradycardia (see section 4.3).</p><p>Experience with fingolimod is limited in patients receiving concurrent therapy with beta blockers, heart-rate-lowering calcium channel blockers (such as verapamil or diltiazem), or other substances which may decrease heart rate (e.g. ivabradine, digoxin, anticholinesteratic agents or pilocarpine). Since the initiation of fingolimod treatment is also associated with slowing of the heart rate (see also section 4.8, Bradyarrhythmia), concomitant use of these substances during treatment initiation may be associated with severe bradycardia and heart block. Because of the potential additive effect on heart rate treatment with fingolimod should not be initiated in patients who are concurrently treated with these substances (see also section 4.5). In such patients, treatment with fingolimod should be considered only if the anticipated benefits outweigh the potential risks. If treatment with fingolimod is considered, advice from a cardiologist should be sought regarding the switch to non-heart rate lowering medicinal products prior to initiation of treatment. If the heart-rate-lowering treatment cannot be stopped, cardiologist&#39;s advice should be sought to determine appropriate first dose monitoring, at least overnight extended monitoring is recommended (see also section 4.5).</p><p><u><strong>QT interval </strong></u></p><p>In a thorough QT interval study of doses of 1.25 or 2.5 mg fingolimod at steady-state, when a negative chronotropic effect of fingolimod was still present, fingolimod treatment resulted in a prolongation of QTcI, with the upper limit of the 90% CI &le;13.0 ms. There is no dose- or exposure response relationship of fingolimod and QTcI prolongation. There is no consistent signal of increased incidence of QTcI outliers, either absolute or change from baseline, associated with fingolimod treatment.</p><p>The clinical relevance of this finding is unknown. In the multiple sclerosis studies, clinically relevant effects on prolongation of the QTc-interval have not been observed but patients at risk for QT prolongation were not included in clinical studies.</p><p>Medicinal products that may prolong QTc interval are best avoided in patients with relevant risk factors, for example, hypokalaemia or congenital QT prolongation.</p><p><u><strong>Immunosuppressive effects</strong></u></p><p>Fingolimod has an immunosuppressive effect that predisposes patients to an infection risk, including opportunistic infections that can be fatal, and increases the risk of developing lymphomas and other malignancies, particularly those of the skin. Physicians should carefully monitor patients, especially those with concurrent conditions or known factors, such as previous immunosuppressive therapy. If this risk is suspected, discontinuation of treatment should be considered by the physician on a case-by-case basis (see also section 4.4 &ldquo;Infections&rdquo; and &ldquo;Cutaneous neoplasms&rdquo; and section 4.8 &ldquo;Lymphomas&rdquo;).</p><p><u><strong>Infections</strong></u></p><p>A core pharmacodynamic effect of fingolimod is a dose-dependent reduction of the peripheral lymphocyte count to 20-30% of baseline values. This is due to the reversible sequestration of lymphocytes in lymphoid tissues (see section 5.1).</p><p>Before initiating treatment with fingolimod, a recent complete blood count (CBC) (i.e. within 6 months or after discontinuation of prior therapy) should be available. Assessments of CBC are also recommended periodically during treatment, at month 3 and at least yearly thereafter, and in case of signs of infection. Absolute lymphocyte count &lt;0.2x10^9 /l, if confirmed, should lead to treatment interruption until recovery, because in clinical studies, fingolimod treatment was interrupted in patients with absolute lymphocyte count &lt;0.2x10^9 /l.</p><p>Initiation of treatment with fingolimod should be delayed in patients with severe active infection until resolution.</p><p>The immune system effects of fingolimod may increase the risk of infections, including opportunistic infections (see section 4.8). Effective diagnostic and therapeutic strategies should be employed in patients with symptoms of infection while on therapy. When evaluating a patient with a suspected infection that could be serious, referral to a physician experienced in treating infections should be considered. During treatment, patients receiving fingolimod should be instructed to report promptly symptoms of infection to their physician.</p><p>Suspension of fingolimod should be considered if a patient develops a serious infection and consideration of benefit-risk should be undertaken prior to re-initiation of therapy.</p><p>Elimination of fingolimod following discontinuation of therapy may take up to two months and vigilance for infection should therefore be continued throughout this period. Patients should be instructed to report symptoms of infection up to 2 months after discontinuation of fingolimod.</p><p><u><strong>Herpes viral infection</strong></u></p><p>Serious, life-threatening, and sometimes fatal cases of encephalitis, meningitis or meningoencephalitis caused by herpes simplex and varicella zoster viruses have occurred with fingolimod at any time during treatment. If herpes encephalitis, meningitis or meningoencephalitis occur, fingolimod should be discontinued and appropriate treatment for the respective infection should be administered.</p><p>Patients need to be assessed for their immunity to varicella (chickenpox) prior to fingolimod treatment. It is recommended that patients without a health care professional confirmed history of chickenpox or documentation of a full course of vaccination with varicella vaccine undergo antibody testing to varicella zoster virus (VZV) before initiating fingolimod therapy. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with fingolimod (see section 4.8). Initiation of treatment with fingolimod should be postponed for 1 month to allow full effect of vaccination to occur.</p><p><u><strong>Cryptococcal meningitis</strong></u></p><p>Cases of cryptococcal meningitis (a fungal infection), sometimes fatal, have been reported in the post-marketing setting after approximately 2-3 years of treatment, although an exact relationship with the duration of treatment is unknown (see section 4.8). Patients with symptoms and signs consistent with cryptococcal meningitis (e.g. headache accompanied by mental changes such as confusion, hallucinations, and/or personality changes) should undergo prompt diagnostic evaluation. If cryptococcal meningitis is diagnosed, fingolimod should be suspended and appropriate treatment should be initiated. A multidisciplinary consultation (i.e. infectious disease specialist) should be undertaken if re-initiation of fingolimod is warranted.</p><p><u><strong>Progressive multifocal leukoencephalopathy</strong></u></p><p>Progressive multifocal leukoencephalopathy (PML) has been reported under fingolimod treatment since marketing authorisation (see section 4.8). PML is an opportunistic infection caused by John Cunningham virus (JCV), which may be fatal or result in severe disability. Cases of PML have occurred after approximately 2-3 years of monotherapy treatment without previous exposure to natalizumab. Although the estimated risk appears to increase with cumulative exposure over time, an exact relationship with the duration of treatment is unknown. Additional PML cases have occurred in patients who had been treated previously with natalizumab, which has a known association with PML. PML can only occur in the presence of a&nbsp;JCV infection. If JCV testing is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV antibody testing has not been studied in fingolimod treated patients. It should also be noted that a negative anti-JCV antibody test does not preclude the possibility of subsequent JCV infection. Before initiating treatment with fingolimod, a baseline MRI should be available (usually within 3 months) as a reference. MRI findings may be apparent before clinical signs or symptoms. During routine MRI (in accordance with national and local recommendations), physicians should pay attention to PML suggestive lesions. MRI may be considered as part of increased vigilance in patients considered at increased risk of PML. Cases of asymptomatic PML based on MRI findings and positive JCV DNA in the cerebrospinal fluid have been reported in patients treated with fingolimod. If PML is suspected, MRI should be performed immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML has been excluded.</p><p><u><strong>Human papilloma virus infection</strong></u></p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations. Cancer screening, including Pap test, is recommended as per standard of care.</p><p><u><strong>Macular oedema</strong></u></p><p>Macular oedema with or without visual symptoms has been reported in 0.5% of patients treated with fingolimod 0.5 mg, occurring predominantly in the first 3-4 months of therapy (see section 4.8). An ophthalmological evaluation is therefore recommended at 3-4 months after treatment initiation. If patients report visual disturbances at any time while on therapy, evaluation of the fundus, including the macula, should be carried out.</p><p>Patients with history of uveitis and patients with diabetes mellitus are at increased risk of macular oedema (see section 4.8). Fingolimod has not been studied in multiple sclerosis patients with concomitant diabetes mellitus. It is recommended that multiple sclerosis patients with diabetes mellitus or a history of uveitis undergo an ophthalmological evaluation prior to initiating therapy and have follow-up evaluations while receiving therapy.</p><p>Continuation of treatment in patients with macular oedema has not been evaluated. It is recommended that fingolimod be discontinued if a patient develops macular oedema. A decision on whether or not fingolimod therapy should be re-initiated after resolution of macular oedema needs to take into account the potential benefits and risks for the individual patient.</p><p><u><strong>Liver injury</strong></u></p><p>Increased hepatic enzymes, in particular alanine aminotransaminase (ALT) but also gamma glutamyltransferase (GGT) and aspartate transaminase (AST) have been reported in multiple sclerosis patients treated with fingolimod. Some cases of acute liver failure requiring liver transplant and clinically significant liver injury have also been reported. Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, have occurred as early as ten days after the first dose and have also been reported after prolonged use. In clinical trials, elevations 3-fold the upper limit of normal (ULN) or greater in ALT occurred in 8.0% of adult patients treated with fingolimod 0.5 mg compared to 1.9% of placebo patients. Elevations 5-fold the ULN occurred in 1.8% of patients on fingolimod and 0.9% of patients on placebo. In clinical trials, fingolimod was discontinued if the elevation exceeded 5 times the ULN. Recurrence of liver transaminase elevations occurred with rechallenge in some patients, supporting a relationship to fingolimod. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. Serum transaminase levels returned to normal within approximately 2 months after discontinuation of fingolimod.</p><p>Fingolimod has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and should not be used in these patients (see section 4.3).</p><p>Due to the immunosuppressive properties of fingolimod, initiation of treatment should be delayed in patients with active viral hepatitis until resolution.</p><p>Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before initiation of treatment. In the absence of clinical symptoms, liver transaminases and serum bilirubin should be monitored at months 1, 3, 6, 9 and 12 on therapy and periodically thereafter until 2 months after fingolimod discontinuation. In the absence of clinical symptoms, if liver transaminases are greater than 3 but less than 5 times the ULN without increase in serum bilirubin, more frequent monitoring including serum bilirubin and alkaline phosphatase (ALP) measurement should be instituted to determine if further increases occur and in order to discern if an alternative aetiology of hepatic dysfunction is present. If liver transaminases are at least 5 times the ULN or at least 3 times the ULN associated with any increase in serum bilirubin, fingolimod should be discontinued. Hepatic monitoring should be continued. If serum levels return to normal (including if an alternative cause of the hepatic dysfunction is discovered), fingolimod may be restarted based on a careful benefit-risk assessment of the patient.</p><p>Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine, should have liver enzymes and bilirubin checked promptly and treatment should be discontinued if significant liver injury is confirmed. Treatment should not be resumed unless a plausible alternative aetiology for the signs and symptoms of liver injury can be established.</p><p>Although there are no data to establish that patients with pre-existing liver disease are at increased risk of developing elevated liver function tests when taking fingolimod, caution in the use of fingolimod should be exercised in patients with a history of significant liver disease.</p><p><u><strong>Blood pressure effects </strong></u></p><p>Patients with hypertension uncontrolled by medication were excluded from participation in premarketing clinical trials and special care is indicated if patients with uncontrolled hypertension are treated with fingolimod.</p><p>In MS clinical trials, patients treated with fingolimod 0.5 mg had an average increase of approximately 3 mmHg in systolic pressure, and approximately 1 mmHg in diastolic pressure, first detected approximately 1 month after treatment initiation, and persisting with continued treatment. In the two-year placebo-controlled study, hypertension was reported as an adverse event in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo. Therefore, blood pressure should be regularly monitored during treatment.</p><p><u><strong>Respiratory effects </strong></u></p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV1) and diffusion capacity for carbon monoxide (DLCO) were observed with fingolimod treatment starting at month 1 and remaining stable thereafter. Fingolimod should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease (see section 4.8).</p><p><u><strong>Posterior reversible encephalopathy syndrome</strong></u></p><p>Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported at the 0.5 mg dose in clinical trials and in the post-marketing setting (see section 4.8). Symptoms reported included sudden onset of severe headache, nausea, vomiting, altered mental status, visual disturbances and seizure. Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral haemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, fingolimod should be discontinued.</p><p><u><strong>Prior treatment with immunosuppressive or immunomodulatory therapies</strong></u></p><p>There have been no studies performed to evaluate the efficacy and safety of fingolimod when switching patients from teriflunomide, dimethyl fumarate or alemtuzumab treatment to fingolimod. When switching patients from another disease modifying therapy to fingolimod, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation. A CBC is recommended prior to initiating fingolimod to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.</p><p>Fingolimod can generally be started immediately after discontinuation of interferon or glatiramer acetate.</p><p>For dimethyl fumarate, the washout period should be sufficient for CBC to recover before treatment with fingolimod is started.</p><p>Due to the long half-life of natalizumab, elimination usually takes up to 2-3 months following discontinuation. Teriflunomide is also eliminated slowly from the plasma. Without an accelerated elimination procedure, clearance of teriflunomide from plasma can take from several months up to 2 years. An accelerated elimination procedure as defined in the teriflunomide summary of product characteristics is recommended or alternatively washout period should not be shorter than 3.5 months. Caution regarding potential concomitant immune effects is required when switching patients from natalizumab or teriflunomide to fingolimod.</p><p>Alemtuzumab has profound and prolonged immunosuppressive effects. As the actual duration of these effects is unknown, initiating treatment with fingolimod after alemtuzumab is not recommended unless the benefits of such treatment clearly outweigh the risks for the individual patient.</p><p>A decision to use prolonged concomitant treatment with corticosteroids should be taken after careful consideration.</p><p><u><strong>Co-administration with potent CYP450 inducers </strong></u></p><p>The combination of fingolimod with potent CYP450 inducers should be used with caution. Concomitant administration with St John&#39;s Wort is not recommended (see section 4.5).</p><p><u><strong>Malignancies</strong></u></p><p><u><strong>Cutaneous malignancies</strong></u></p><p>Basal cell carcinoma (BCC) and other cutaneous neoplasms, including malignant melanoma, squamous cell carcinoma, Kaposi&#39;s sarcoma and Merkel cell carcinoma, have been reported in patients receiving fingolimod (see section 4.8). Vigilance for skin lesions is warranted and a medical evaluation of the skin is recommended at initiation, and then every 6 to 12 months taking into consideration clinical judgement. The patient should be referred to a dermatologist in case suspicious lesions are detected.</p><p>Since there is a potential risk of malignant skin growths, patients treated with fingolimod should be cautioned against exposure to sunlight without protection. These patients should not receive concomitant phototherapy with UV-B-radiation or PUVA-photochemotherapy</p><p><strong><u>Lymphomas</u></strong></p><p>There have been cases of lymphoma in clinical studies and the post-marketing setting (see section 4.8). The cases reported were heterogeneous in nature, mainly non-Hodgkin&#39;s lymphoma, including B-cell and T-cell lymphomas. Cases of cutaneous T-cell lymphoma (mycosis fungoides) have been observed. A fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma has also been observed. If lymphoma is suspected, treatment should be discontinued.</p><p><u><strong>Women of childbearing potential</strong></u></p><p>Due to risk to the foetus, fingolimod is contraindicated during pregnancy and in women of childbearing potential not using effective contraception. Before initiation of treatment, women of childbearing potential must be informed of this risk to the foetus, must have a negative pregnancy test and must use effective contraception during treatment and for 2 months after treatment discontinuation (see sections 4.3 and 4.6 and the information contained in the Physician Information Pack).</p><p><u><strong>Tumefactive lesions</strong></u></p><p>Rare cases of tumefactive lesions associated with MS relapse were reported in the postmarketing setting. In case of severe relapses, MRI should be performed to exclude tumefactive lesions. Discontinuation of treatment should be considered by the physician on a case-by-case basis taking into account individual benefits and risks.</p><p><u><strong>Return of disease activity (rebound) after fingolimod discontinuation </strong></u></p><p>In the post-marketing setting, severe exacerbation of disease has been observed rarely in some patients stopping fingolimod. This has generally been observed within 12 weeks after stopping fingolimod, but has also been reported up to 24 weeks after fingolimod discontinuation. Caution is therefore indicated when stopping fingolimod therapy. If discontinuation of fingolimod is deemed necessary, the possibility of recurrence of exceptionally high disease activity should be considered and patients should be monitored for relevant signs and symptoms and appropriate treatment initiated as required (see &ldquo;Stopping therapy&rdquo; below).</p><p><u><strong>Stopping therapy</strong></u></p><p>If a decision is made to stop treatment with fingolimod a 6 week interval without therapy is needed, based on half-life, to clear fingolimod from the circulation (see section 5.2). Lymphocyte counts progressively return to normal range within 1-2 months of stopping therapy in most patients (see section 5.1) although full recovery can take significantly longer in some patients. Starting other therapies during this interval will result in concomitant exposure to fingolimod. Use of immunosuppressants soon after the discontinuation of fingolimod may lead to an additive effect on the immune system and caution is therefore indicated.</p><p>Caution is also indicated when stopping fingolimod therapy due to the risk of a rebound (see &ldquo;Return of disease activity (rebound) after fingolimod discontinuation&rdquo; above). If discontinuation of fingolimod is deemed necessary, patients should be monitored during this time for relevant signs of a possible rebound.</p><p><u><strong>Interference with serological testing</strong></u></p><p>Since fingolimod reduces blood lymphocyte counts via re-distribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilised to evaluate the lymphocyte subset status of a patient treated with fingolimod. Laboratory tests involving the use of circulating mononuclear cells require larger blood volumes due to reduction in the number of circulating lymphocytes.</p><p><u><strong>Paediatric population </strong></u></p><p>The safety profile in paediatric patients is similar to that in adults and the warnings and precautions for adults therefore also apply to paediatric patients.</p><p>In particular, the following should be noted when prescribing fingolimod to paediatric patients:</p><p>&bull; Precautions should be followed at the time of the first dose (see &ldquo;Bradyarrhythmia&rdquo; above). The same precautions as for the first dose are recommended when patients are switched from the 0.25 mg to the 0.5 mg daily dose.</p><p>&bull; In the controlled paediatric trial D2311, cases of seizures, anxiety, depressed mood and depression have been reported with a higher incidence in patients treated with fingolimod compared to patients treated with interferon beta-1a. Caution is required in this subgroup population (see &ldquo;Paediatric population&rdquo; in section 4.8).</p><p>&bull; Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.</p><p>&bull; It is recommended that paediatric patients complete all immunisations in accordance with current immunisation guidelines before starting fingolimod therapy (see &ldquo;Infections&rdquo; above).</p><p>&bull; There are very limited data available in children between 10&ndash;12 years old, less than 40 kg or at Tanner stage &lt;2 (see sections 4.8 and 5.1). Caution is required in these subgroups due to very limited knowledge available from the clinical study.</p><p>&bull; Long-term safety data in the paediatric population are not available.</p><p><u><strong>Excipients</strong></u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Anti-neoplastic, immunomodulatory or immunosuppressive therapies </strong></u></p><p>Anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be coadministered due to the risk of additive immune system effects (see sections 4.3 and 4.4).</p><p>Caution should also be exercised when switching patients from long-acting therapies with immune effects such as natalizumab, teriflunomide or mitoxantrone (see section 4.4). In&nbsp;multiple sclerosis clinical studies the concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection.</p><p><u><strong>Vaccination </strong></u></p><p>During and for up to two months after treatment with fingolimod vaccination may be less effective. The use of live attenuated vaccines may carry a risk of infections and should therefore be avoided (see sections 4.4 and 4.8).</p><p><u><strong>Bradycardia-inducing substances</strong></u></p><p>Fingolimod has been studied in combination with atenolol and diltiazem. When fingolimod was used with atenolol in an interaction study in healthy volunteers, there was an additional 15% reduction of heart rate at fingolimod treatment initiation, an effect not seen with diltiazem. Treatment with fingolimod should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate, such as class Ia and III antiarrhythmics, calcium channel blockers (such as verapamil or diltiazem), ivabradine, digoxin, anticholinesteratic agents or pilocarpine because of the potential additive effects on heart rate (see sections 4.4 and 4.8). If treatment with fingolimod is considered in such patients, advice from a cardiologist should be sought regarding the switch to non-heart-rate lowering medicinal products or appropriate monitoring for treatment initiation, at least overnight monitoring is recommended, if the heart rate-lowering medication cannot be stopped.</p><p><u><strong>Pharmacokinetic interactions of other substances on fingolimod</strong></u></p><p>Fingolimod is metabolised mainly by CYP4F2. Other enzymes like CYP3A4 may also contribute to its metabolism, notably in the case of strong induction of CYP3A4. Potent inhibitors of transporter proteins are not expected to influence fingolimod disposition. Co-administration of fingolimod with ketoconazole resulted in a 1.7-fold increase in fingolimod and fingolimod phosphate exposure (AUC) by inhibition of CYP4F2. Caution should be exercised with substances that may inhibit CYP3A4 (protease inhibitors, azole antifungals, some macrolides such as clarithromycin or telithromycin).</p><p>Co-administration of carbamazepine 600 mg twice daily at steady-state and a single dose of fingolimod 2 mg reduced the AUC of fingolimod and its metabolite by approximately 40%. Other strong CYP3A4 enzyme inducers, for example rifampicin, phenobarbital, phenytoin, efavirenz and St. John&#39;s Wort, may reduce the AUC of fingolimod and its metabolite at least to this extent. As this could potentially impair the efficacy, their co-administration should be used with caution. Concomitant administration with St. John&#39;s Wort is however not recommended (see section 4.4).</p><p><u><strong>Pharmacokinetic interactions of fingolimod on other substances</strong></u></p><p>Fingolimod is unlikely to interact with substances mainly cleared by the CYP450 enzymes or by substrates of the main transporter proteins.</p><p>Co-administration of fingolimod with ciclosporin did not elicit any change in the ciclosporin or fingolimod exposure. Therefore, fingolimod is not expected to alter the pharmacokinetics of medicinal products that are CYP3A4 substrates.</p><p>Co-administration of fingolimod with oral contraceptives (ethinylestradiol and levonorgestrel) did not elicit any change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestagens, however an effect of fingolimod on their exposure is not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u></p><p>US FDA Pregnancy Category: C.</p><p><u><strong>Women of childbearing potential / Contraception in females</strong></u></p><p>Fingolimod is contraindicated in women of childbearing potential not using effective contraception (see section 4.3). Therefore, before initiation of treatment in women of childbearing potential, a negative pregnancy test result must be available and counselling should be provided regarding the serious risk to the foetus. Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation of fingolimod, since fingolimod takes approximately 2 months to eliminate from the body after treatment discontinuation (see section 4.4).</p><p>Specific measures are also included in the Physician Information Pack. These measures must be implemented before fingolimod is prescribed to female patients and during treatment.</p><p>When stopping fingolimod therapy for planning a pregnancy the possible return of disease activity should be considered (see section 4.4).</p><p><u><strong>Pregnancy </strong></u></p><p>Based on human experience, post-marketing data suggest that use of fingolimod is associated with a 2-fold increased risk of major congenital malformations when administered during pregnancy compared with the rate observed in the general population (2-3%; EUROCAT).</p><p>The following major malformations were most frequently reported:</p><p>&bull; Congenital heart disease such as atrial and ventricular septal defects, tetralogy of Fallot.</p><p>&bull; Renal abnormalities.</p><p>&bull; Musculoskeletal abnormalities.</p><p>There are no data on the effects of fingolimod on labour and delivery.</p><p>Animal studies have shown reproductive toxicity including foetal loss and organ defects, notably persistent truncus arteriosus and ventricular septal defect (see section 5.3). Furthermore, the receptor affected by fingolimod (sphingosine 1-phosphate receptor) is known to be involved in vascular formation during embryogenesis.</p><p>Consequently, fingolimod is contraindicated during pregnancy (see section 4.3). Fingolimod should be stopped 2 months before planning a pregnancy (see section 4.4). If a woman becomes pregnant during treatment, fingolimod must be discontinued. Medical advice should be given regarding the risk of harmful effects to the foetus associated with treatment and ultrasonography examinations should be performed.</p><p><u><strong>Breastfeeding</strong></u></p><p>Fingolimod is excreted in milk of treated animals during lactation (see section 5.3). Due to the potential for serious adverse reactions to fingolimod in nursing infants, women receiving fingolimod should not breastfeed.</p><p><u><strong>Fertility</strong></u></p><p>Data from preclinical studies do not suggest that fingolimod would be associated with an increased risk of reduced fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fingolimod has no or negligible influence on the ability to drive and use machines.</p><p>However, dizziness or drowsiness may occasionally occur when initiating therapy with fingolimod. On initiation of fingolimod treatment it is recommended that patients be observed for a period of 6 hours (see section 4.4, Bradyarrhythmia).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Summary of the safety profile</strong></u></p><p>The most frequent adverse reactions (incidence &ge;10%) at the 0.5 mg dose were headache (24.5%), hepatic enzyme increased (15.2%), diarrhoea (12.6%), cough (12.3%), influenza (11.4%), sinusitis (10.9%) and back pain (10.0%).</p><p><u><strong>Tabulated list of adverse reactions</strong></u></p><p>Adverse reactions reported in clinical trials and derived from post-marketing experience via spontaneous case reports or literature cases are shown below. Frequencies were defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Influenza Sinusitis</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Herpes viral infections Bronchitis</p><p>Tinea versicolor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy (PML)**</p><p>Cryptococcal infections**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Basal cell carcinoma</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malignant melanoma****</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Lymphoma***</p><p>Squamous cell carcinoma****</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Kaposi&#39;s sarcoma****</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Lymphopenia Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Autoimmune haemolytic anaemia*** Peripheral oedema***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, including rash, urticaria and angioedema upon treatment initiation***</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Depressed mood</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness Migraine</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizure</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:659px"><tbody><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:557px"><p>Posterior reversible encephalopathy syndrome (PRES)*</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top; width:557px"><p>Severe exacerbation of disease after fingolimod discontinuation***</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:557px"><p>Macular oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Bradycardia Atrioventricular block</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top; width:557px"><p>T-wave inversion***</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Hypertension</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:557px"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Dyspnoea</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:557px"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:557px"><p>Nausea***</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top; width:557px"><p>Acute hepatic failure***</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Eczema Alopecia Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:557px"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Myalgia Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:557px"><p>Asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:557px"><p>Hepatic enzyme increased (increased alanine transaminase, gamma glutamyltransferase, aspartate transaminase)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:658px"><tbody><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:393px"><p>Weight decreased***</p><p>Blood triglycerides increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:393px"><p>Neutrophil count decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:657px"><p>* The frequency category was based on estimated exposure of approximately 10, 000 patients to fingolimod in all clinical trials.</p><p>** PML and cryptococcal infections (including cases of cryptococcal meningitis) have been reported in the post- marketing setting (see section 4.4).</p><p>*** Adverse drug reactions from spontaneous reports and literature.</p><p>**** The frequency category and risk assessment were based on an estimated exposure of more than 24,000 patients to fingolimod 0.5 mg in all clinical trials.</p></td></tr></tbody></table><p><strong><u>Description of selected adverse reactions</u></strong></p><p><strong><em><u>Infections</u></em></strong></p><p>In multiple sclerosis clinical studies the overall rate of infections (65.1%) at the 0.5 mg dose was similar to placebo. However, lower respiratory tract infections, primarily bronchitis and to a lesser extent herpes infection and pneumonia were more common in fingolimod-treated patients.</p><p>Some cases of disseminated herpes infection, including fatal cases, have been reported even at the 0.5 mg dose.</p><p>In the post-marketing setting, cases of infections with opportunistic pathogens, such as viral (e.g. varicella zoster virus [VZV], John Cunningham virus [JCV] causing Progressive Multifocal Leukoencephalopathy, herpes simplex virus [HSV]), fungal (e.g. cryptococci including cryptococcal meningitis) or bacterial (e.g. atypical mycobacterium), have been reported, some of which have been fatal (see section 4.4).</p><p>Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting. Due to the immunosuppressive properties of fingolimod, vaccination against HPV should be considered prior to treatment initiation with fingolimod taking into account vaccination recommendations. Cancer screening, including Pap test, is recommended as per standard of care.</p><p><u><strong>Macular oedema </strong></u></p><p>In multiple sclerosis clinical studies macular oedema occurred in 0.5% of patients treated with the recommended dose of 0.5 mg and 1.1% of patients treated with the higher dose of 1.25 mg. The majority of cases occurred within the first 3-4 months of therapy. Some patients presented with blurred vision or decreased visual acuity, but others were asymptomatic and diagnosed on routine ophthalmological examination. The macular oedema generally improved or resolved spontaneously after discontinuation of treatment. The risk of recurrence after re-challenge has not been evaluated.</p><p>Macular oedema incidence is increased in multiple sclerosis patients with a history of uveitis (17% with a history of uveitis vs. 0.6% without a history of uveitis). Fingolimod has not been studied in multiple sclerosis patients with diabetes mellitus, a disease which is associated with an increased risk for macular oedema (see section 4.4). In renal transplant clinical studies in which patients with diabetes mellitus were included, therapy with fingolimod 2.5 mg and 5 mg resulted in a 2-fold increase in the incidence of macular oedema.</p><p><u><strong>Bradyarrhythmia</strong></u></p><p>Initiation of treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays. In multiple sclerosis clinical studies the maximal decline in heart rate was seen within 6 hours after treatment initiation, with declines in mean heart rate of 12-13 beats per minute for fingolimod 0.5 mg. Heart rate below 40 beats per minute in adults, and below 50 beats per minute in paediatric patients, was rarely observed in patients on fingolimod 0.5 mg. The average heart rate returned towards baseline within 1 month of chronic treatment. Bradycardia was generally asymptomatic but some patients experienced mild to moderate symptoms, including hypotension, dizziness, fatigue and/or palpitations, which resolved within the first 24 hours after treatment initiation (see also sections 4.4 and 5.1).</p><p>In multiple sclerosis clinical studies first-degree atrioventricular block (prolonged PR interval on ECG) was detected after treatment initiation in adult and paediatric patients. In adult clinical trials it occurred in 4.7% of patients on fingolimod 0.5 mg, in 2.8% of patients on intramuscular interferon beta-1a, and in 1.6% of patients on placebo. Second-degree atrioventricular block was detected in less than 0.2% adult patients on fingolimod 0.5 mg. In the post-marketing setting, isolated reports of transient, spontaneously resolving complete AV block have been observed during the six hour monitoring period following the first dose of fingolimod. The patients recovered spontaneously. The conduction abnormalities observed both in clinical trials and post-marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation. Although most patients did not require medical intervention, one patient on fingolimod 0.5 mg received isoprenaline for asymptomatic second-degree Mobitz I atrioventricular block.</p><p>In the post-marketing setting, isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose. These cases have been confounded by concomitant medicinal products and/or pre-existing disease. The relationship of such events to fingolimod is uncertain.</p><p><u><strong>Blood pressure </strong></u></p><p>In multiple sclerosis clinical studies fingolimod 0.5 mg was associated with an average increase of approximately 3 mmHg in systolic pressure and approximately 1 mmHg in diastolic pressure, manifesting approximately 1 month after treatment initiation. This increase persisted with&nbsp;continued treatment. Hypertension was reported in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo. In the post-marketing setting, cases of hypertension have been reported within the first month of treatment initiation and on the first day of treatment that may require treatment with antihypertensive agents or discontinuation of fingolimod (see also section 4.4, Blood pressure effects).</p><p><u><strong>Liver function</strong></u></p><p>Increased hepatic enzymes have been reported in adult and paediatric multiple sclerosis patients treated with fingolimod. In clinical studies 8.0% and 1.8% of adult patients treated with fingolimod 0.5 mg experienced an asymptomatic elevation in serum levels of ALT of &ge;3x ULN (upper limit of normal) and &ge;5x ULN, respectively. Recurrence of liver transaminase elevations has occurred upon re-challenge in some patients, supporting a relationship to the medicinal product. In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months. ALT levels returned to normal within approximately 2 months after discontinuation of treatment. In a small number of patients (N=10 on 1.25 mg, N=2 on 0.5 mg) who experienced ALT elevations &ge;5x ULN and who continued on fingolimod therapy, the ALT levels returned to normal within approximately 5 months (see also section 4.4, Liver function).</p><p><u><strong>Nervous system disorders</strong></u></p><p>In clinical studies, rare events involving the nervous system occurred in patients treated with fingolimod at higher doses (1.25 or 5.0 mg) including ischaemic and haemorrhagic strokes and neurological atypical disorders, such as acute disseminated encephalomyelitis (ADEM)-like events.</p><p>Cases of seizures, including status epilepticus, have been reported with the use of fingolimod in clinical studies and in the post-marketing setting.</p><p><u><strong>Vascular disorders</strong></u></p><p>Rare cases of peripheral arterial occlusive disease occurred in patients treated with fingolimod at higher doses (1.25 mg).</p><p><u><strong>Respiratory system</strong></u></p><p>Minor dose-dependent reductions in values for forced expiratory volume (FEV1) and diffusion capacity for carbon monoxide (DLCO) were observed with fingolimod treatment starting at month 1 and remaining stable thereafter. At month 24, the reduction from baseline values in percentage of predicted FEV1 was 2.7% for fingolimod 0.5 mg and 1.2% for placebo, a difference that resolved after treatment discontinuation. For DLCO the reductions at month 24 were 3.3% for fingolimod 0.5 mg and 2.7% for placebo (see also section 4.4 Respiratory effects).</p><p><u><strong>Lymphomas</strong></u></p><p>There have been cases of lymphoma of different varieties, in both clinical studies and the post marketing setting, including a fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma. The incidence of non-Hodgkin&#39;s lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population. Some T-cell lymphoma cases were also reported in the post-marketing setting, including cases of cutaneous T-cell lymphoma (mycosis fungoides) (see also section 4.4 Malignancies).</p><p><u><strong>Haemophagocytic syndrome </strong></u></p><p>Very rare cases of haemophagocytic syndrome (HPS) with fatal outcome have been reported in patients treated with fingolimod in the context of an infection. HPS is a rare condition that has been described in association with infections, immunosuppression and a variety of autoimmune diseases.</p><p><u><strong>Paediatric population</strong></u></p><p>In the controlled paediatric trial D2311 (see section 5.1), the safety profile in paediatric patients (10 to below 18 years of age) receiving fingolimod 0.25 mg or 0.5 mg daily was overall similar to that seen in adult patients. There were, nevertheless, more neurological and psychiatric disorders observed in the study. Caution is needed in this subgroup due to very limited knowledge available from the clinical study.</p><p>In the paediatric study, cases of seizures were reported in 5.6% of fingolimod-treated patients and 0.9% of interferon beta-1a-treated patients.</p><p>Depression and anxiety are known to occur with increased frequency in the multiple sclerosis population. Depression and anxiety have also been reported in paediatric patients treated with fingolimod.</p><p>Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 80 times the recommended dose (0.5 mg) were well tolerated in healthy adult volunteers. At 40 mg, 5 of 6 subjects reported mild chest tightness or discomfort which was clinically consistent with small airway reactivity.</p><p>Fingolimod can induce bradycardia upon treatment initiation. The decline in heart rate usually starts within one hour of the first dose, and is steepest within 6 hours. The negative chronotropic effect of fingolimod persists beyond 6 hours and progressively attenuates over subsequent days of treatment (see section 4.4 for details). There have been reports of slow atrioventricular conduction, with isolated reports of transient, spontaneously resolving complete AV block (see sections 4.4 and 4.8).</p><p>If the overdose constitutes first exposure to fingolimod, it is important to monitor patients with a continuous (real time) ECG and hourly measurement of heart rate and blood pressure, at least during the first 6 hours (see section 4.4).</p><p>Additionally, if after 6 hours the heart rate is &lt;45 bpm in adults, &lt;55 bpm in paediatric patients aged 12 years and above, or &lt;60 bpm in paediatric patients aged 10 years to below 12 years, or if the ECG at 6 hours after the first dose shows second degree or higher AV block, or if it shows a QTc interval &ge;500 msec, monitoring should be extended at least for overnight and until the findings have resolved. The occurrence at any time of third degree AV block should also lead to extended monitoring including overnight monitoring.</p><p>Neither dialysis nor plasma exchange results in removal of fingolimod from the body.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA27.</p><p><u><strong>Mechanism of action </strong></u></p><p>Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. Fingolimod phosphate binds at low nanomolar concentrations to sphingosine 1-phosphate (S1P) receptor 1 located on lymphocytes, and readily crosses the blood-brain barrier to bind to S1P receptor 1 located on neural cells in the central nervous system (CNS). By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes. Animal studies have shown that this redistribution reduces the infiltration of pathogenic lymphocytes, including pro-inflammatory Th17 cells, into the CNS, where they would be involved in nerve inflammation and nervous tissue damage. Animal studies and in vitro experiments indicate that fingolimod may also act via interaction with S1P receptors on neural cells.</p><p><u><strong>Pharmacodynamic effects</strong></u></p><p>Within 4-6 hours after the first dose of fingolimod 0.5 mg, the lymphocyte count decreases to approximately 75% of baseline in peripheral blood. With continued daily dosing, the lymphocyte count continues to decrease over a two-week period, reaching a minimal count of approximately 500 cells/microliter or approximately 30% of baseline. Eighteen percent of patients reached a minimal count below 200 cells/microliter on at least one occasion. Low lymphocyte counts are maintained with chronic daily dosing. The majority of T and B lymphocytes regularly traffic through lymphoid organs and these are the cells mainly affected by fingolimod. Approximately 15-20% of T lymphocytes have an effect on memory phenotype, cells that are important for peripheral immune surveillance. Since this lymphocyte subset typically does not traffic to lymphoid organs it is not affected by fingolimod. Peripheral lymphocyte count increases are evident within days of stopping fingolimod treatment and typically normal counts are reached within one to two months. Chronic fingolimod dosing leads to a mild decrease in the neutrophil count to approximately 80% of baseline. Monocytes are unaffected by fingolimod.</p><p>Fingolimod causes a transient reduction in heart rate and decrease in atrioventricular conduction at treatment initiation (see sections 4.4 and 4.8). The maximal decline in heart rate is seen within 6 hours post dose, with 70% of the negative chronotropic effect achieved on the first day. With continued administration heart rate returns to baseline within one month. The decrease in heart rate induced by fingolimod can be reversed by parenteral doses of atropine or isoprenaline. Inhaled salmeterol has also been shown to have a modest positive chronotropic effect. With initiation of fingolimod treatment there is an increase in atrial premature contractions, but there is no increased rate of atrial fibrillation/flutter or ventricular arrhythmias or ectopy. Fingolimod treatment is not associated with a decrease in cardiac output. Autonomic responses of the heart, including diurnal variation of heart rate and response to exercise are not affected by fingolimod treatment.</p><p>S1P4 could partially contribute to the effect but was not the main receptor responsible for the lymphoid depletion. The mechanism of action of bradycardia and vasoconstriction were also studied in vitro in guinea pigs and isolated rabbit aorta and coronary artery. It was concluded that bradycardia could be mediated primarily by activation of inward-rectifying potassium channel or G-protein activated inwardly rectifying K+ channel (IKACh/GIRK) and that vasoconstriction seems to be mediated by a Rho kinase and calcium dependent mechanism.</p><p>Fingolimod treatment with single or multiple doses of 0.5 and 1.25 mg for two weeks is not associated with a detectable increase in airway resistance as measured by FEV1 and forced expiratory flow rate (FEF) 25-75. However, single fingolimod doses &ge;5 mg (10-fold the&nbsp;recommended dose) are associated with a dose-dependent increase in airway resistance. Fingolimod treatment with multiple doses of 0.5, 1.25, or 5 mg is not associated with impaired oxygenation or oxygen desaturation with exercise or an increase in airway responsiveness to methacholine. Subjects on fingolimod treatment have a normal bronchodilator response to inhaled beta-agonists.</p><p><u><strong>Clinical efficacy and safety </strong></u></p><p>The efficacy of fingolimod has been demonstrated in two studies which evaluated once-daily doses of fingolimod 0.5 mg and 1.25 mg in adult patients with relapsing-remitting multiple sclerosis (RRMS). Both studies included adult patients who had experienced &ge;2 relapses in the prior 2 years or &ge;1 relapse during the prior year. Expanded Disability Status Score (EDSS) was between 0 and 5.5. A third study targeting the same adult patient population was completed after registration of fingolimod.</p><p>Study D2301 (FREEDOMS) was a 2-year randomised, double-blind, placebo-controlled Phase III study of 1,272 patients (n=425 on 0.5 mg, 429 on 1.25 mg, 418 on placebo). Median values for baseline characteristics were: age 37 years, disease duration 6.7 years, and EDSS score 2.0. Outcome results are shown in Table 1. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards either endpoint.</p><p><strong>Table 1 Study D2301 (FREEDOMS): main results</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.18**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse- free at 24 months</p></td><td style="vertical-align:top"><p>70%**</p></td><td style="vertical-align:top"><p>46%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed</p><p>Disability Progression&dagger;</p><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>17%</p><p>0.70 (0.52, 0.96)*</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.5)**</p></td><td style="vertical-align:top"><p>5.0 (9.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month 24</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.7 (-0.8)**</p></td><td style="vertical-align:top"><p>-1.0 (-1.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>** p&lt;0.001, *p&lt;0.05 compared to placebo.</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients who completed the 24-month core FREEDOMS study could enter a dose-blinded extension study (D2301E1) and receive fingolimod. In total, 920 patients entered (n=331 continued on 0.5 mg, 289 continued on 1.25 mg, 155 switched from placebo to 0.5 mg and 145 switched from placebo to 1.25 mg). After 12 months (month 36), 856 patients (93%) were still enrolled. Between months 24 and 36, the annualised relapse rate (ARR) for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.17 (0.21 in the core study).</p><p>The ARR for patients who switched from placebo to fingolimod 0.5 mg was 0.22 (0.42 in the core study).</p><p>Comparable results were shown in a replicate 2-year randomised, double-blind, placebocontrolled Phase III study on fingolimod in 1,083 patients (n=358 on 0.5 mg, 370 on 1.25 mg, 355 on placebo) with RRMS (D2309; FREEDOMS 2). Median values for baseline characteristics were: age 41 years, disease duration 8.9 years, EDSS score 2.5.</p><p><strong>Table 2 Study D2309 (FREEDOMS 2): main results</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.21**</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 24 months</p></td><td style="vertical-align:top"><p>71.5%**</p></td><td style="vertical-align:top"><p>52.7%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed Disability</p><p>Progression&dagger;</p><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>25%</p><p>0.83 (0.61, 1.12)</p></td><td style="vertical-align:top"><p>29%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 24 months</p></td><td style="vertical-align:top"><p>0.0 (2.3)**</p></td><td style="vertical-align:top"><p>4.0 (8.9)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at month 24</p></td><td style="vertical-align:top"><p>0.0 (0.4)**</p></td><td style="vertical-align:top"><p>0.0 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 24 months</p></td><td style="vertical-align:top"><p>-0.71 (-0.86)**</p></td><td style="vertical-align:top"><p>-1.02 (-1.28)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>** p&lt;0.001 compared to placebo.</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p>Study D2302 (TRANSFORMS) was a 1-year randomised, double-blind, double-dummy, active (interferon beta-1a)-controlled Phase III study of 1,280 patients (n=429 on 0.5 mg, 420 on 1.25 mg, 431 on interferon beta-1a, 30 &mu;g by intramuscular injection once weekly). Median values for baseline characteristics were: age 36 years, disease duration 5.9 years, and EDSS score 2.0.</p><p>Outcome results are shown in Table 3. There were no significant differences between the 0.5 mg and the 1.25 mg doses as regards study endpoints.</p><p><strong>Table 3 Study D2302 (TRANSFORMS): main results</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Interferon beta-1a, 30</strong></p><p><strong>&mu;g</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.16**</p></td><td style="vertical-align:top"><p>0.33</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse-free at 12 months</p></td><td style="vertical-align:top"><p>83%**</p></td><td style="vertical-align:top"><p>71%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 3-month Confirmed Disability</p><p>Progression&dagger;</p><p>Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>6%</p><p>0.71 (0.42, 1.21)</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of new or enlarging T2 lesions over 12 months</p></td><td style="vertical-align:top"><p>0.0 (1.7)*</p></td><td style="vertical-align:top"><p>1.0 (2.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) number of Gd-enhancing lesions at 12 months</p></td><td style="vertical-align:top"><p>0.0 (0.2)**</p></td><td style="vertical-align:top"><p>0.0 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median (mean) % change in brain volume over 12 months</p></td><td style="vertical-align:top"><p>-0.2 (-0.3)**</p></td><td style="vertical-align:top"><p>-0.4 (-0.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&dagger; Disability progression defined as 1-point increase in EDSS confirmed 3 months later.</p><p>* p&lt;0.01,** p&lt;0.001, compared to interferon beta-1a.</p><p>All analyses of clinical endpoints were intent-to-treat. MRI analyses used evaluable dataset.</p></td></tr></tbody></table><p>Patients who completed the 12-month core TRANSFORMS study could enter a dose-blinded extension (D2302E1) and receive fingolimod. In total, 1,030 patients entered, however, 3 of these patients did not receive treatment (n=356 continued on 0.5 mg, 330 continued on 1.25 mg, 167 switched from interferon beta-1a to 0.5 mg and 174 from interferon beta-1a to 1.25 mg). After 12 months (month 24), 882 patients (86%) were still enrolled. Between months 12 and 24, the ARR for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.20 (0.19 in the core study). The ARR for patients who switched from interferon beta-1a to fingolimod 0.5 mg was 0.33 (0.48 in the core study).</p><p>Pooled results of Studies D2301 and D2302 showed a consistent and statistically significant reduction in annualised relapse rate compared to comparator in subgroups defined by gender, age, prior multiple sclerosis therapy, disease activity or disability levels at baseline.</p><p>Further analyses of clinical trial data demonstrate consistent treatment effects in highly active subgroups of relapsing remitting multiple sclerosis patients.</p><p><u><strong>Paediatric population</strong></u></p><p>The efficacy and safety of once-daily doses of fingolimod 0.25 mg or 0.5 mg (dose selected based on body weight and exposure measurements) have been established in paediatric patients aged 10 to &lt;18 years with relapsing-remitting multiple sclerosis.</p><p>Study D2311 (PARADIGMS) was a double-blind, double-dummy, active-controlled study with flexible duration up to 24 months, with 215 patients 10 to &lt;18 years old (n=107 on fingolimod, 108 on interferon beta-1a 30 &mu;g by intramuscular injection once weekly).</p><p>Median values for baseline characteristics were: age 16 years, median disease duration 1.5 years and EDSS score 1.5. The majority of patients were Tanner stage 2 or higher (94.4%) and were &gt;40 kg (95.3%). Overall, 180 (84%) of patients completed the core phase on study drug (n=99 [92.5%] on fingolimod, 81 [75%] on interferon beta-1a). Outcome results are shown in Table 4.</p><p><strong>Table 4 Study D2311 (PARADIGMS): main results</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:697px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Fingolimod&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.25 mg or 0.5 mg</strong></p></td><td style="vertical-align:top; width:39px"><p><strong>Interferon beta-1a</strong></p><p><strong>30 &mu;g</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p>N=107</p></td><td style="vertical-align:top; width:39px"><p>N=107#</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate (primary endpoint)</p></td><td style="vertical-align:top"><p>0.122**</p></td><td style="vertical-align:top; width:39px"><p>0.675</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients remaining relapse- free at 24 months</p></td><td style="vertical-align:top"><p>85.7**</p></td><td style="vertical-align:top; width:39px"><p>38.8</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:696px"><p><strong>MRI endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of the number of new or newly enlarging T2 lesions</p></td><td style="vertical-align:top"><p>n=106</p></td><td style="vertical-align:top; width:39px"><p>n=102</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>4.393**</p></td><td style="vertical-align:top; width:39px"><p>9.269</p></td></tr><tr><td style="vertical-align:top"><p>Number of Gd-enhancing T1 lesions per scan up to month 24</p></td><td style="vertical-align:top"><p>n=105</p></td><td style="vertical-align:top; width:39px"><p>n=95</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean</p></td><td style="vertical-align:top"><p>0.436**</p></td><td style="vertical-align:top; width:39px"><p>1.282</p></td></tr><tr><td style="vertical-align:top"><p>Annualised rate of brain atrophy from baseline up to month 24</p></td><td style="vertical-align:top"><p>n=96</p></td><td style="vertical-align:top; width:39px"><p>n=89</p></td></tr><tr><td style="vertical-align:top"><p>Least Square Mean</p></td><td style="vertical-align:top"><p>-0.48*</p></td><td style="vertical-align:top; width:39px"><p>-0.80</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:696px"><p># One patient randomised to receive interferon beta-1a by intramuscular injection was unable to swallow the double- dummy medication and discontinued from study. The patient was excluded from the full analysis and safety set.</p><p>* p&lt;0.05, ** p&lt;0.001, compared to interferon beta-1a.</p><p>All analyses of clinical endpoints were on the full analysis set.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic data were obtained in healthy adult volunteers, in renal transplant adult patients and in multiple sclerosis adult patients.</p><p>The pharmacologically active metabolite responsible for efficacy is fingolimod phosphate.</p><p><strong><u>Absorption</u></strong></p><p>Fingolimod absorption is slow (tmax of 12-16 hours) and extensive (&ge;85%). The apparent absolute oral bioavailability is 93% (95% confidence interval: 79-111%). Steady-state-blood concentrations are reached within 1 to 2 months following once-daily administration and steady-state levels are approximately 10-fold greater than with the initial dose.</p><p>Food intake does not alter Cmax or exposure (AUC) of fingolimod. Fingolimod phosphate Cmax was slightly decreased by 34% but AUC was unchanged. Therefore, fingolimod may be taken without regard to meals (see section 4.2).</p><p><u><strong>Distribution </strong></u></p><p>Fingolimod highly distributes in red blood cells, with the fraction in blood cells of 86%. Fingolimod phosphate has a smaller uptake in blood cells of&nbsp;&lt;17%&nbsp;Fingolimod and fingolimod phosphate are highly protein bound (&gt;99%).</p><p>Fingolimod is extensively distributed to body tissues with a volume of distribution of about 1,200&plusmn;260 liters. A study in four healthy subjects who received a single intravenous dose of a radioiodolabelled analogue of fingolimod demonstrated that fingolimod penetrates into the brain. In a study in 13 male multiple sclerosis patients who received fingolimod 0.5 mg/day, the mean amount of fingolimod (and fingolimod phosphate) in seminal ejaculate, at steady-state, was approximately 10,000 times lower than the oral dose administered (0.5 mg).</p><p><u><strong>Biotransformation</strong></u></p><p>Fingolimod is transformed in humans by reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod phosphate. Fingolimod is eliminated by oxidative biotransformation catalysed mainly via CYP4F2 and possibly other isoenzymes and subsequent fatty acid-like degradation to inactive metabolites. Formation of pharmacologically inactive non-polar ceramide analogues of fingolimod was also observed. The main enzyme involved in the metabolism of fingolimod is partially identified and may be either CYP4F2 or CYP3A4.</p><p>Following single oral administration of [14^C] fingolimod, the major fingolimod-related components in blood, as judged from their contribution to the AUC up to 34 days post dose of total radiolabelled components, are fingolimod itself (23%), fingolimod phosphate (10%), and inactive metabolites (M3 carboxylic acid metabolite (8%), M29 ceramide metabolite (9%) and M30 ceramide metabolite (7%)).</p><p><u><strong>Elimination</strong></u></p><p>Fingolimod blood clearance is 6.3&plusmn;2.3 l/h, and the average apparent terminal half-life (t1/2) is 6-9 days. Blood levels of fingolimod and fingolimod phosphate decline in parallel in the terminal phase, leading to similar half-lives for both.</p><p>After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod phosphate are not excreted intact in urine but are the major components in the faeces, with amounts representing less than 2.5% of the dose each. After 34 days, the recovery of the administered dose is 89%.</p><p><u><strong>Linearity </strong></u></p><p>Fingolimod and fingolimod phosphate concentrations increase in an apparently dose proportional manner after multiple once-daily doses of 0.5 mg or 1.25 mg.</p><p><u><strong>Characteristics in specific groups of patients </strong></u></p><p><u><strong>Gender, ethnicity and renal impairment</strong></u></p><p>The pharmacokinetics of fingolimod and fingolimod phosphate do not differ in males and females, in patients of different ethnic origin, or in patients with mild to severe renal impairment.</p><p><u><strong>Hepatic impairment</strong></u></p><p>In subjects with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, and C), no change in fingolimod Cmax was observed, but fingolimod AUC was increased respectively by 12%, 44%, and 103%. In patients with severe hepatic impairment (Child-Pugh class C), fingolimodphosphate Cmax was decreased by 22% and AUC was not substantially changed. The pharmacokinetics of fingolimod-phosphate were not evaluated in patients with mild or moderate hepatic impairment.</p><p>The apparent elimination half-life of fingolimod is unchanged in subjects with mild hepatic impairment, but is prolonged by about 50% in patients with moderate or severe hepatic impairment.</p><p>Fingolimod should not be used in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3). Fingolimod should be introduced cautiously in mild and moderate hepatic impaired patients (see section 4.2).</p><p><u><strong>Elderly population </strong></u></p><p>Clinical experience and pharmacokinetic information in patients aged above 65 years are limited. Fingolimod should be used with caution in patients aged 65 years and over (see section 4.2).</p><p><u><strong>Paediatric population</strong></u></p><p>In paediatric patients (10 years of age and above), fingolimod-phosphate concentrations increase in an apparent dose proportional manner between 0.25 mg and 0.5 mg.</p><p>Fingolimod-phosphate concentration at steady state is approximately 25% lower in paediatric patients (10 years of age and above) following daily administration of 0.25 mg or 0.5 mg fingolimod compared to the concentration in adult patients treated with fingolimod 0.5 mg once daily.</p><p>There are no data available for paediatric patients below 10 years old.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of fingolimod was assessed in mice, rats, dogs and monkeys. The major target organs were the lymphoid system (lymphopenia and lymphoid atrophy), lungs (increased weight, smooth muscle hypertrophy at the bronchio-alveolar junction), and heart (negative chronotropic effect, increase in blood pressure, perivascular changes and myocardial degeneration) in several species; blood vessels (vasculopathy) in rats only at doses of 0.15 mg/kg and higher in a 2-year study, representing an approximate 4-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>No evidence of carcinogenicity was observed in a 2-year bioassay in rats at oral doses of fingolimod up to the maximally tolerated dose of 2.5 mg/kg, representing an approximate 50- fold margin based on human systemic exposure (AUC) at the 0.5 mg dose. However, in a 2-year mouse study, an increased incidence of malignant lymphoma was seen at doses of 0.25 mg/kg and higher, representing an approximate 6-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>Fingolimod was neither mutagenic nor clastogenic in animal studies.</p><p>Fingolimod had no effect on sperm count/motility or on fertility in male and female rats up to the highest dose tested (10 mg/kg), representing an approximate 150-fold margin based on human systemic exposure (AUC) at a daily dose of 0.5 mg.</p><p>Fingolimod was teratogenic in the rat when given at doses of 0.1 mg/kg or higher. Drug exposure in rats at this dose was similar to that in patients at the therapeutic dose (0.5 mg). The most common foetal visceral malformations included persistent truncus arteriosus and ventricular septum defect. The teratogenic potential in rabbits could not be fully assessed, however an increased embryo-foetal mortality was seen at doses of 1.5 mg/kg and higher, and a decrease in viable foetuses as well as foetal growth retardation was seen at 5 mg/kg. Drug exposure in rabbits at these doses was similar to that in patients.</p><p>In rats, F1 generation pup survival was decreased in the early postpartum period at doses that did not cause maternal toxicity. However, F1 body weights, development, behaviour, and fertility were not affected by treatment with fingolimod.</p><p>Fingolimod was excreted in milk of treated animals during lactation at concentrations 2-fold to 3-fold higher than that found in maternal plasma. Fingolimod and its metabolites crossed the placental barrier in pregnant rabbits.</p><p><u><strong>Juvenile animal studies </strong></u></p><p>Results from two toxicity studies in juvenile rats showed slight effects on neurobehavioural response, delayed sexual maturation and a decreased immune response to repeated stimulations with keyhole limpet haemocyanin (KLH), which were not considered adverse. Overall, the treatment-related effects of fingolimod in juvenile animals were comparable to those seen in adult rats at similar dose levels, with the exception of changes in bone mineral density and neurobehavioural impairment (reduced auditory startle response) observed at doses of 1.5 mg/kg and higher in juvenile animals and the absence of smooth muscle hypertrophy in the lungs of the juvenile rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsule content:</p><p>&minus; Betacyclodextrin,</p><p>&minus; Magnesium stearate.</p><p>Capsule shell:</p><p>&minus; Iron oxide yellow,</p><p>&minus; Titanium dioxide,</p><p>&minus; Gelatin,</p><p>&minus; Sodium lauryl sulphate.</p><p>Printing ink:</p><p>&minus; Shellac,</p><p>&minus; Black iron oxide,</p><p>&minus; Potassium hydroxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Figoya 0.5 mg Hard Capsules are packed in PVC/Aclar-Aluminium blister packs.</p><p>Pack size: 28 Hard Capsules (4 blisters of 7&rsquo;s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrazi Pharmaceutical Industries Factory Co.,
2nd Industrial City, Street no. 67, Cross 110, P.O. Box 3992,
Dammam, Kingdom of Saudi Arabia
Tel.: +966 13 8281919,
Fax: +966 13 8281313,
E-mail: info@alrazi-pharma.com
Website: www.alrazi-pharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                14 September 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>